

**UNIVERSITY OF NEW MEXICO BOARD OF REGENTS'
STUDENT SUCCESS, TEACHING, AND RESEARCH COMMITTEE MEETING**

**April 15, 2025
9:30AM
SUB Ballroom B
AGENDA**

I. Call to Order

- Confirmation of a Quorum

II. Adoption of Agenda

III. Approval of Meeting Minutes from December 5, 2024

IV. Provost's Administrative Report

James P. Holloway, Provost & EVP for Academic Affairs

- Member Comments
- Advisor Comments

V. Consent Item[s]:

1. **GCERT Environmental Sensing, Data, and Modeling** **TAB V-1**
Christopher Lippitt, Associate Professor, Department of Geography & Environmental Studies
2. **Request approval to create the 'Peter A. Winograd Endowed Clinical Research Professorship'** **TAB V-2**
Bill Uher, VP HSC Development, UNM Foundation
3. **Request approval to appoint Dr. Neda Hashemi as the inaugural holder of the Peter A. Winograd Endowed Clinical Research Professorship.** **TAB V-3**
Bill Uher, VP HSC Development, UNM Foundation
4. **KUNM Radio Board Annual Report** **TAB V-4**
Richard Towne, General Manager

VI. Action Item[s]:

1. **Request Adoption of the Security Managerial Group Resolution** **TAB VI-1**
Jessica Hermosillo, Facility Security Officer
Patrick Bourgoyne, Assistant Facility Security Officer
2. **Request approval of proposed revisions to policy, C140 "Extra Compensation"** **TAB VI-2**
Cris Elder, President, Faculty Senate

**UNIVERSITY OF NEW MEXICO BOARD OF REGENTS'
STUDENT SUCCESS, TEACHING, AND RESEARCH COMMITTEE MEETING**

**April 15, 2025
9:30AM
SUB Ballroom B**

Recommendations for Consent Agenda Items to Full Board of Regents' Agenda

Paula Tackett, Regent, and Chair, SSTAR Committee

VII. Informational Item[s]:

- | | |
|---|------------------|
| 1. Annual Course Fee Review Report | TAB VII-1 |
| <i>Pamela Cheek, PhD., Vice Provost for Student Success</i> | |
| <i>Nicole Dopson, Assistant Vice President for Academic Resource Management</i> | |
| 2. Federal Research Funding Impact | TAB VII-2 |
| <i>Ellen Fisher, Vice President for Research and Economic Development</i> | |
| 3. Community Engagement Report | TAB VII-3 |
| <i>Tim Castillo, Director Community Engagement Initiatives</i> | |

Adjournment

**UNIVERSITY OF NEW MEXICO BOARD OF REGENTS'
STUDENT SUCCESS, TREACHING, AND RESAEARCH COMMITTEE MEETING**

**February 3, 2025
MEETING MINUTES**

Committee members present: *Regent and Chair Paula Tackett, Regent Victor Reyes, Regent Rob Schwartz, Provost & Executive Vice President for Academic Affairs, James Holloway, Faculty Senate President, Cris Elder (via Zoom), and Staff Council President Ivan Olay*

Committee members absent: *NA*

Administration present: *Sr. Vice Provost Barabara Rodriguez, Vice Provost for Student Success, Pamela Cheek, Assistant Vice Provost for Faculty Affairs, Christopher Lyons, General Counsel, Scot Sauder, Vice President for Research, Ellen Fisher, Vice President for Enrollment Management, Dan Garcia, Vice President for Student Affairs, Eric Scott, Assistant Vice President for Academic Resource Management, Executive Director for Global Education Initiatives, Nicole Tami, Provost's Chief of Staff, Jennifer Love, and Sr. Communication and Marketing Manager, Kimberly Delker*

Advisors present: *GPSA President, Anthony Tomaziefski, ASUNM President, Michel Rivera Ramirez*

Advisors absent: *NA*

Staff: *Pamela Kirchner, Executive Assistant to Provost Holloway and Vice Provost Pamela Cheek, Emily Morelli, Secretary to the Board of Regents,*

CALL TO ORDER AND CONFIRMATION OF A QUORUM

Regent Chair Paula Tackett called the meeting to order at 12:05 PM in the Roberts Room in Scholes Hall and confirmed a quorum with five members in person and one member virtually.

VOTE TO APPROVE THE AGENDA

- **The motion to adopt the agenda passed unanimously with three committee members present and one virtually. (1st Holloway, 2nd Reyes)**

APPROVAL OF MINUTES

- **The motion to approve the minutes of the December 5, 2024, regular meeting, with corrections to typographical errors passed unanimously. (1st Holloway, 2nd Schwartz)**

PROVOST'S ADMINISTRATIVE REPORT

Provost Holloway presented enrollment numbers for sprint term that are up 3.3% in Albuquerque compared to same time last year. Three of the branch campuses, Gallup, Taos, and Valencia showed significant increases as well. Los Alamos had a 23% decrease. There is a small increase in retention rates as well. Fall to Spring retention rate is 89.57%. This is up a half of percentage from last year. Retention rates have continually shown increases.

V. Reyes: What does 0.5 percentage mean in terms of number of students?

Provost Holloway: I have it on my computer. I will get that to you.

Multiyear Budget Planning is continuing. At the last meeting we showed data per unit. Now we are categorizing requests under the academic affairs units. Again, this is the process that we bring into the budget leadership team to help us think about how we are going to spend the cored fund, the combination of state supported I&G and tuition that comes into the non-health units. This helps us set other parameters for the university around compensation, cost of benefits, etc. In the academic affairs units, we categorize

UNIVERSITY OF NEW MEXICO BOARD OF REGENTS'
STUDENT SUCCESS, TEACHING, AND RESEARCH COMMITTEE MEETING

February 3, 2025
MEETING MINUTES

things into faculty lines, about \$2.5M in requests for new faculty lines and everything from teacher education to fine arts, engineering, and other disciplines. This year we encouraged requests for supplemental compensation. Unites requested \$2.4M for faculty supplemental compensation; equity increases. We reported at the last meeting that we have a little over \$11M gap in faculty salaries within academic affairs units. This is relative to the averages of institutions like ours. If we were to find these funds, that would close the gap. We also have requests for supplemental salaries for staff, totaling about \$1M. The deployment of new tools like our SPET tool, we can see staff salary and equities much more clearly within the institution and to some degree with respect to marketing. Equally units are looking for more staff. In the decade 2008-2018, the number of staff supporting our activities was reduced quite a lot. Operational funds were also significantly reduced during the same period. This put a large strain on existing staff, in some cases, moving staff work to faculty. To address the staff shortage, there is about \$4.5M of requests for staff lines. There is also a request for \$2.6M in operational funds. We have seen large units, like the Department of English work with operating funds in the \$20-25K range. Graduate student support requested \$2.7M to fill gaps caused by increases in graduate student stipends, as we have negotiated new contracts to increase competitiveness in specific areas. There is a significant number of departments looking for additional TAs and RAs to help with teaching due to increased enrollment. These are the requests that I presented to the budget leadership team earlier in January. Decisions about any of the requests have not been made yet. This is just to get a sense of the magnitude of needs. Over the next weeks, we will put together an actual budget based on our understanding of expected revenues, compensations increase costs for insurance, not health insurance, property liability insurance. Federal funding pause. On Jan 27, 2025, the Office of Management and Budget issued memo M-25-13 which directed federal funding agencies to pause all payments to grant recipients such as UNM to allow all of those agencies to align their spending with the 45 executive orders that the new administration has put out since January 20, 2025. To provide a sense of how the system works and what the implications could be, the way federal spending works for us is we spend \$1 and then go to the federal government and ask for our \$1. It is always a reimbursement model. We are constantly going to payment portals to submit invoices so that funds will be transferred to us. We essentially front our cash for funds that the federal government has promised. This includes Pell grants, which is a big one, research grant support, financial aid. It is also things like loans. If we have a loan coming from the federal government that would be affected. We do not currently have loans. The hospital tower loan is already paid, but those are the kinds of things impacted by the orders.

After the OMB order, various portals were closed at various times. The memo M-25-13 was rescinded via another memo from OMB, M-25-14 on Jan 29, however various funding portals remained closed, notably that of the NSF. The NSF portal was reopened late this weekend. UNM is owed roughly \$4M per week in reimbursements from the federal government, so the closure of these portals is a significant concern. There are various court cases, and a temporary restraining order was issued. The NSF reopened their portal on Sunday. I will also mention that we have received either a stop work order, which means stop work, stop spending; we will not reimburse you for any work you do from this point forward for 3 grants. We received another order that simply canceled a grant. All of these are concerning as these grants pay students and faculty and the impact is felt immediately, particularly their paycheck. We have chosen to continue to work where we did not get a specific stop work order or cancellation. It is risky, but it is the right thing to do, at least for now. I am comfortable with where we are right now. We are looking at all our grants, approximately 1,900 across HSC and main campus and reviewing them against the forty-five executive orders. There are about fifteen of the executive orders that look like that have some immediate relevance to us, positively or negatively.

UNIVERSITY OF NEW MEXICO BOARD OF REGENTS'
STUDENT SUCCESS, TEACHING, AND RESEARCH COMMITTEE MEETING

February 3, 2025
MEETING MINUTES

E. Fisher: I want to add that not ordinarily are the people that get paid directly off of grants out money in terms of us not getting paid, but we also charge overhead (F&A) on all of these grants. Those funds are used to support the research offices on health sciences and on main campus. We are 100% funded on F&A. We do not have any state funding to back up the offices. Not only do we have researchers at risk in both offices, but we also have staff at risk in both offices as well.

Provost Holloway: There is a set of grants that are very important to our branch campuses. Our Taos campus is more than 50% funded on grants, mostly federal grants like Title V, Title III, etc. Some of the branch campuses have a lot of exposure here. Title V grants, for example, are about growing the capacity of HIS institutions. On Friday, the Department of Education took down their primary HSI website and the executive orders certainly have the implication that, the administration does not support programs like Title V. Title V is in statute but many of the other programs that were paused were in statute or supported by congressional appropriations. As an HSI institution, we have some particular additional risks that we need to be mindful of.

Member Questions/Comments.

V. Reyes: Do you point out Pell because that is sources with federal funds or is there an executive order that touches Pell?

Provost Holloway: I point out Pell because it is a huge source of federal funds and very important to our students and when the orders came out it would have literally paused the payments to us for Pell. We made the decision to continue to pay out federally funded financial aid, the federally funded financial aid, works study, etc. There is other financial aid from the federal government that is less direct, and it remained unclear whether it was impacted or not. I do not think Pell is a risk.

V. Reyes: What does the total amount look like, all the staff that Dr. Fisher references that are supported by federal funds?

Provost Holloway: We are doing estimates on that now, but the number we are seeing is \$4M to \$5M in federal support each week.

E. Fisher: The reason that it is challenging to get a hard number is that some of the state funding we receive is actually federal flow through. When we get it from the state, we count it as state funding as opposed to federal funding, but it is federal flow through. Roughly speaking about 80% of our research dollars come from the feds. Last year we did about \$380M in research expenditures, so 80% of \$380M is at the lower end. The other 20% is coming from the state, which a portion is also federal flow through. If there were a complete shutdown of all federal funding to the university, we are looking at, roughly 90% of our total research dollars.

Provost Holloway: The three stop work orders we have seen, and the one cancellation are not going to make a huge difference. It is three out of 1900. Presumably, this is just the beginning of a larger set. Trying to identify what grants might be at risk here up front is very much at the forefront.

E. Fisher: One of the things we are doing is trying to analyze things that are high, medium, and low risk. Again, this is a rough estimate, but if you take things that are identifiably at a high risk that could be seen as not in alignment with the executive orders, I will say 10-20% is where we are sitting if taken at face value based on titles for projects.

Provost Holloway: Did your estimate of 10-20% include climate change research?

E. Fisher: No. I've got a list of 44/45 grants identified that were identified as having climate or conservation in the title. This is a very quick first pass at title searching for words that may be problematic. That was about \$18M. Again, it is unclear if they cancel everything then we are talking closer to \$30-\$40M. It is a moving target in terms of how we evaluate it. Don't hold me to these numbers

UNIVERSITY OF NEW MEXICO BOARD OF REGENTS'
STUDENT SUCCESS, TEACHING, AND RESEARCH COMMITTEE MEETING

February 3, 2025
MEETING MINUTES

they are estimates. My 10-20% came from identifying high risk projects, approximately \$18M off the top.

Provost Holloway: Let us set aside Pell and financial aid that we think are safe. A good portion of federal funding supports research so there are considerations. These are not conclusion or decisions. We may decide we should use I&G funding to bridge people who are on grants that are canceled. We cannot do that long term, but it is something we can consider. Where it is I&G is immaterial. We could consider bridging people so they can either develop a new line of research or redo a grant that is called into question. A number of universities have bridging systems for people supported by research. The ones I know of are much larger than us and they have been doing it for a long time. This is a consideration we can make. The other alternative is for those that are on soft money and do not have grants coming in, may be terminated or furloughed, simply not be paid. Similarly, with staff who are on those kinds of funds. The challenge with doing that you lose talented people. Bridging allows you to retain talented people until they can develop the funding stream to support them. Those are the kinds of considerations we must work through.

Ivan Olay: How will we know if a grant we have will be flagged or may be affected?

E. Fisher: We will notify you.

C. Elder: do we have any indication of what the federal administrations move could mean for academic freedom in relation to teaching?

Provost Holloway: Nothing in the executive orders to date implicates curriculum in any direct way. It may implicate curriculum in indirect ways in the sense that faculty research often flows into their teaching and the change in the funding climate may change faculty research. We are not seeing anything that speaks to the ability of an institution to have the courses and programs it thinks are appropriate.

V. Reyes: To circle back on Taos. Is that a place where there are bridge funds where we should have impact; that we would be able to hold over in particular?

Provost Holloway: One of the things we have done at all our locations is try to build up reserves. This is the kind of situation that reserves let you make decisions on.

Chair Tackett: have we given any thought to approaching the legislature with other institutions because this is not just going to impact us, to see if they would create a bridging fund?

Provost Holloway: there has been very little discussion about this. We will have to have deeper discussions. It is a tricky spot in the legislature because we are asking for so much else.

Chair Tackett: I do not think it hurts to ask or see if that is an option that they would consider.

CONSENT ITEMS:

1. Request approval to create an endowed professorship, Davis-Kozoll Endowed Professorship for Preventions Research and Practice
2. Request approval to appoint Dr. Carmella Kahn as the inaugural holder of the Davis-Kozoll Endowed Professorship for Prevention Research and Practice.
3. Request approval to appoint Christopher Amos, PhD, as the recipient of the Carolyn R. Surface Endowed Chari in Cancer Population and Data Science.
4. New Certificate Program: Welding Tech, UNM Taos
5. New Certificate Program: Medical Biotechnology, UNM Valencia

UNIVERSITY OF NEW MEXICO BOARD OF REGENTS'
STUDENT SUCCESS, TEACHING, AND RESEARCH COMMITTEE MEETING

February 3, 2025
MEETING MINUTES

6. New AA Psychology, UNM Valencia

- **The motion to approve consent items one through six passed unanimously (1st Reyes, 2nd Holloway).**
- **Regent & Chair Tackett recommended consent items 1 through 6 be placed as consent items to the full board. (1st Holloway, 2nd Schwartz)**

ACTION ITEMS:

NA

STRATEGIC DISCUSSION ITEM[s]:

Gainful Employment and Post Graduation Outcomes (presentation attached)

Charla Orozco, Director of Institutional Analytics talked about a couple of different federal accountability measures that we are aligning with the Office of Institutional Analytics. The measures are gainful employment, financial value transparency and the post-secondary employment outcomes. These measures were born of this idea of an open transparent accountability measure for institutions and for students who are graduating with degrees and certificates to make sure that they are actually getting some financial gain. In order to continue receiving Higher Education Act funds, institutions must prepare student for gainful employment in a recognized occupation.

Equitable Access Program (presentation attached)

Alicia Solano, Assistant Vice President for Institutional Support Services and Peg Lewis, UNM Course Material manager talked about equitable access to course materials and how educational material has evolved over the last decade towards digital format, either eBooks or inclusive access. As these formats have gained momentum, printed textbooks have declined. Course materials are easier to obtain through online access, reducing overall costs. UNM is setting up a new course materials model called equitable access. EA bridges access to digital format material, OER (learning and research resources free for public use) materials. EA is a university wide initiative that has benefits that align with the UNM 2040, goals 2,3, and 4: student experience and educational innovation, inclusive excellence, and sustainability, respectively. Benefits: participating students will have access to all their required course materials for one low cost per semester. Alicia provided survey results showing a positive academic impact for students.

C. Elder: What was the response rate for this survey.

A. Solano: I will look at the report we had and get back to you.

Alicia provided statistics showing that 74% of course materials sold at the bookstore in FY24 were in digital format. There was an increase to 80% in Fall 24. Academic year 2023-2024 students saved approximately \$8.3M in course material.

Fall 2025 implementation of the EA program. Will include all Albuquerque undergraduate students. \$279 flat-rate per semester for 2025-2026 academic year. Faculty choose material and formats they want to use in each course. Payments will be processed through the bursar's office as bookstore charge. Flexibility for students to opt out of EA.

**UNIVERSITY OF NEW MEXICO BOARD OF REGENTS'
STUDENT SUCCESS, TREACHING, AND RESAEARCH COMMITTEE MEETING**

**February 3, 2025
MEETING MINUTES**

If students have not accessed any of the materials during a semester, they will be eligible for a full refund.

V. Reyes: There is no harm in continuing to talk about this. Cris, Ivan, and I represent constituencies, and we would like to just continue to have a conversation about this, even if it is about the rollout. This is a new fee that people have not seen before and whether the fee would traditionally be what the fees we discussed at the Board of Regents are, it is something that is obviously very important. I am not calling for this to be slowed down. I would just like more information.

Provost Holloway: I would like to correct one fact on the table. This is very important to Donna Riley in engineering. Engineering is 27% white. It is not majority white.

KUNM Radio Board

Regents hold the license for KUNM. There are nine stations all together. The regent's policy from 1988 charters the KUNM Radio Board. Among their bylaw responsibilities is an annual report. We reach just over half of the state's population. KUNM's contributing listeners and local program sponsors provide about \$1.8M of the station's annual cash budget of about 2.3M. Our measured audience has held steady for five years with is good news with all the digital and podcast competitors. Volunteers play a significant role in success of KUNM. Volunteers contribute over 16K hours per year. The board is working with the station management and volunteers to develop a modernized draft mission statement which will align with UNM 2040.

The Board wants to recognize people who had volunteers at KUNM for a long time and who have passed. Claude Stevenson, volunteered 47 years, Alan Liddel, 22 years, and Matthew Pinch, our music directed died unexpectedly in August. He worked with us for 20 years.

KUNM received a variety of awards in FY 2023-2024; noted in the presentation. Richard Towne announced his retirement in 2025. Livingston Associates is conducting a national search for a new General Manager. Candidates will be interview in Spring 2025.

V. Reyes: Thanked Richard for his 30 years and for making a station we can all be proud of.

R. Schwartz expressed his agreement. Stating that Richard has done an extraordinary job as the station serves an important function in New Mexico, not just UNM, but across the state.

C. Elder: Richard, you have been able to bring together the expertise, professionalism, and the humanity, which, I hope we all strive for. You model it so well. Thank you for all you have done.

Richard Towne was given a standing ovation.

ADJOURN

There being no further business, Regent Tackett asked for a motion to adjourn the meeting; Regent Reyes motioned; Provost Holloway seconded; all were in favor. The meeting adjourned at 2:14 PM.

Environmental Sensing, Data, and Modeling

A Graduate Certificate



DEPARTMENT OF
GEOGRAPHY &
ENVIRONMENTAL STUDIES

Environmental Sensing, Data, and Modeling Program Overview



1 Course from Each Competency Area (12-16 credits)

1. Spatial Data Science
2. Remote Sensing
3. Spatial Data Communication
4. Environmental Modeling

Program Learning Outcomes (PLOs)

1. Evaluate and apply advanced spatial data models to accurately represent diverse environmental phenomena, critically assessing model suitability for various environmental systems.
2. Utilize remote sensing techniques to collect, process, and interpret data for mapping and quantifying environmental characteristics, ensuring accuracy through rigorous validation methods.
3. Create and present high-quality maps and spatial data visualizations tailored to various audiences, employing appropriate cartographic standards and spatial analysis tools to effectively convey environmental information.
4. Develop and apply spatial modeling techniques to simulate and analyze interactions between environmental phenomena, evaluating model outcomes and their implications for environmental decision-making and management.

Why?

- Explicit Credential in Geographic Information Science (GIScience)
- Employment in GIS-related fields is projected to grow faster than average for all occupations (BLS 2023)
- GIS market is expected to reach \$134.23 billion globally by 2030 (Directions Magazine)
- 100% job placement for Graduate Students in GIScience M.S. track



Who?

Based on existing GIScience Course Enrollment, enrollment is expected to draw from:

- Biology
- Earth and Planetary Science
- Anthropology
- Civil Engineering
- Business
- Architecture and Planning
- Geography

Based on demand at other universities, strong potential for:

- Public Health
- Sociology
- History
- Psychology
- Communications & Journalism

Courses from several departments count towards the degree:

- Geography and Environmental Studies
- Earth & Planetary Sciences
- Civil Engineering

This program is in direct alignment with UNM's new university-wide center, Accelerating Resilience Innovation in Drylands (ARID)



DEPARTMENT OF
GEOGRAPHY &
ENVIRONMENTAL STUDIES

Expense Projection

Item	Year 1	Year 2	Year 3	Year 4	Year 5
Faculty	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Library	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Physical Facilities	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Equipment & Technology	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Operating	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00

Existing faculty and resources are sufficient to operate this program.



DEPARTMENT OF
GEOGRAPHY &
ENVIRONMENTAL STUDIES

DATE: February 27, 2025

TO: Board of Regents Student Success, Teaching, and Research Committee

FROM: Nancy D. Middlebrook, University Secretary *Nancy D. Middlebrook*

SUBJECT: Curricula Approval from the Faculty Senate

The Faculty Senate approved the proposed new graduate certificate in Environmental Sensing, Data, and Modeling at the February 25, 2025, meeting.

I am writing to request that this item be placed on the agenda for the next Board of Regents Student Success, Teaching, and Research Committee meeting for consideration.

Attachment

GCERT Environ Sensing Data Model Environmental Sensing, Data, and Modeling

Under Review | Fall 2025

Proposal Information

Workflow Status

In Progress

Faculty Senate Approval, Faculty Senate

expand ▲

Waiting for Approval | Faculty Senate Approval

Nancy Middlebrook

Theresa Sherman

Proposal Information

Sponsoring faculty/staff member

Chris Lippitt

Sponsoring faculty/staff email

clippitt@unm.edu

College

College of Arts & Sciences:
Social Sciences &
Interdisciplinary

Department

Geography & Environmental
Studies

Campus

Main Campus

Effective Term and Year

Proposed Effective Term and Year

Fall 2025

Justification

Program Justification

Students across the academy benefit from training in the collection, analysis, and visualization of spatial data. The tools, practices, and theories that enable Geographic Information Systems (GIS), Remote Sensing, and Spatial Modeling, commonly known as Geographic Information Science (GIScience) or Spatial Data Science, are core to many of the fastest-growing sectors of the economy including health care, renewable energy development, environmental management, forestry, mining, intelligence, and social services. According to an Emergent Research report in Directions Magazine, the GIS market is projected to reach \$134.23 billion by 2030. Employment across the many titles that encompass the sector is projected to grow at a faster than average rate (Bureau of Labor Statistics 2023), with many bachelor's and Master's level positions commanding six-figure starting salaries (Glassdoor.com). For the past 2-3 decades, professionals with degrees from across the academy have relied on a small number of GIScience-related courses to increase the marketability of their primary degree. Others have turned those extra few courses into the focus of their entire career; the current Vice President of Geospatial at Bohannon-Houston Inc., one of the largest engineering services firms in the western United States, took a few GIS courses as an employment safety net to his degrees in Spanish. A certificate focused on these skills will allow students to gain a credential in this very marketable skill a powerful supplement to any degree UNM offers.

Program Category and Level

Program Category	Program Level	Degree, Minor, or Certificate Name
Certificate	Graduate	Environmental Sensing, Data, and Modeling

Degree Type

Certificate (graduate)

Degree/Certificate Level	CIP Code ⓘ	CIP Title ⓘ
Graduate Certificate	45.0702	Cartography

Is this program also offered online?

No

New program courses

Composition of new program

Existing courses	Revised courses	New Courses	Total Credits
15	0	0	12-13

Pre-proposal (new degrees/certificates only)

Pre-proposal Executive Summary ⓘ

- ESM_Cert_08302023.docx
- Graduate Certificate Env Sensing 2.pdf

Program Duplication

At UNM, there is no direct duplication. The Department of Geography and Environmental Studies offers related B.S., M.S., and Ph.D. degrees but no certificate. The next closest duplication at UNM comes from UNM Continuing Education courses, which result in CEUs.

Correspondence

- Re: New Certificate Program.pdf

Pre-proposal Approved?

Approved

File uploads

Proposal File Upload ⓘ

- ESM_Cert_08302023.pdf
- Graduate_Certificate_NewHED_ESM_10182024.docx

Associated Forms

Select any associated course forms that exist

Select any associated program forms that exist

Catalog Information

Program Description

This graduate certificate in Environmental Sensing, Data, and Modeling (ESDM) may be earned through successfully completing the program requirements outlined below. The certificate is designed to provide knowledge and competencies to enhance a student's graduate degree or serve as a credential for open university graduate students while providing exposure to a range of topics and techniques in Geographic Information Science as it applies to environmental characterization and systems modeling.

Admissions Requirements

Active graduate student at UNM.

Graduation Requirements

A student's program of study must satisfy the following requirements, completing one course from each of the four program areas:

Spatial Data Science

Remote Sensing

Spatial Data Communication

Modeling Environments

Topics courses need a Program Director's approval to count toward the certificate, as the topics vary from semester to semester.

Professional Credential/Licensure Program Information

License/Certification associated with program

No

Concentrations

Program Concentrations

Code

Title

Concentration Required

No

Certificate Information

Certificate Requirements

- Complete all of the following
 - Spatial Data Science:
 - Complete at least 1 of the following:
 - GEOG525 - Advanced GIScience Seminar (3)
 - GEOG527 - Introductory Programming for GIS (3)
 - GEOG528 - Open Source GIS Programming (3)
 - GEOG580L - Spatial Statistics (3)
 - GEOG581L - Introduction to GIS for Graduate Students (3)
 - GEOG588L - GIS Concepts and Techniques (3)
 - EPS555L - Computational and GIS Applications in Geomorphology (3)
 - Remote Sensing:
 - Complete at least 1 of the following:
 - GEOG524 - Advanced Remote Sensing Seminar (3)
 - GEOG583L - Remote Sensing Fundamentals (4)
 - GEOG584L - Applications of Remote Sensing (4)
 - Spatial Data Communication:
 - Complete at least 1 of the following:
 - GEOG585L - Interactive Web Mapping (3)
 - GEOG586L - Applied GIS and Spatial Analysis (3)
 - Modeling Environments:
 - Complete at least 1 of the following:
 - GEOG523 - Environmental Systems Modeling (3)
 - EPS576 - Physical Hydrology (3)
 - CE547 - GIS in Water Resources Engineering (3)
 - EPS522 - Selected Topics in Geophysics (3)
 - GEOG587L - Geocomputation and Spatial Modeling (3)

Grand Total Credits: 12 - 13

MEMORANDUM

Date: March 12, 2025

To: UNM Board of Regents Student Success, Teaching, and Research Committee

From: Nancy Middlebrook, Ph.D., University Secretary



Re: Approval Request NM Comprehensive Cancer Center

Upon recommendation from the New Mexico Comprehensive Cancer Center, the University Naming Committee reviewed and voted to recommend approval for the following request:

Request approval to create the **‘Peter A. Winograd Endowed Clinical Research Professorship’** endowed professorship.

(3.2.6 Endowed Faculty Positions)

Request approval to appoint **Dr. Neda Hashemi** as the inaugural holder of the Peter A. Winograd endowed Clinical Research Professorship.

(2.2 Private Financial Support)

The request was forwarded to President Stokes for her review and approval. That approval was received on Feb. 27, 2025. Materials for the request and approval are attached for reference.


With the recommended approvals from the University Naming Committee and President Stokes, we respectfully request that this item be placed on the Student Success, Teaching, and Research Committee’s meeting agenda for consideration by the Regents.

Attachments


About the Peter A. Winograd Endowed Clinical Research Professorship

Peter A. Winograd is a 46-year cancer survivor and was treated for melanoma at the UNM Comprehensive Cancer Center by Dr. John H. Saiki. He considers his years of survival to be "borrowed time," and has tried to make the most of them. To support the Cancer Center, Peter has created this professorship to attract and retain the brightest research talent here to New Mexico.

He is a Professor Emeritus at the University of New Mexico School of Law. He joined the UNM law faculty as associate dean in 1976 and became a tenured professor in 1981. Over the years, Peter Winograd has played significant roles in a number of national associations, including the Law School Admission Council, the Association of American Law Schools, and the American Bar Association. Peter Winograd earned degrees from Brown University (B.A., 1960), Harvard Law School (J.D., 1963), and New York University School of Law (LL.M., 1965). He has been admitted to the Bar in New Mexico and the District of Columbia.



Nominee



Dr. Neda Hashemi

**Sponsoring Donor:
Peter A. Winograd**

Dr. Hashemi completed her residency at the University of Texas in Houston and her fellowship at Indiana University. In her distinguished career, she has received many awards and honors. Most recently, she was awarded the National Cancer Institute Early Career Cancer Clinical Investigator Award (NCI ECIA) in 2024 and had been nominated for ASCO Leadership Program by the UNMCCC leadership. She currently serves as an Associate Professor and full member of the UNMCCC, where she holds key leadership positions, including Leader of the Genitourinary (GU) Clinical Working Group, Chair of the Protocol Review and Monitoring Committee (PRMC), and Medical Director of the New Mexico Cancer Research Alliance (NMCRA).

As a medical oncologist and leader of the GU Clinical Working Group at UNMCCC, Dr. Hashemi is committed to improving outcomes for patients with GU cancers through clinical research and expanded access to trials, particularly for underserved populations. She has successfully built a multidisciplinary collaboration with urologic and radiation oncology teams, enhancing the clinical trial portfolio with a balanced mix of NCI-sponsored (NCTN), industry, and investigator-initiated studies. She has served as a principal investigator and co-investigator on numerous trials conducted through NRG Oncology, SWOG, ECOG, and the Alliance for Clinical Trials in Oncology. Additionally, she is the NCI Community Oncology Research Program (NCORP) representative for the NCI GU Cancers Steering Committee (GUSC) Prostate Cancer Task Force, a member of the GU Working Group of the Hoosier Cancer Research Network (HCRN), and a member of the Immuno-Oncology Committee of the Alliance for Clinical Trials in Oncology.

Dr. Hashemi is also dedicated to mentoring the next generation of oncologists. Her contributions to education and mentorship have been recognized with several prestigious awards, including the **Research Mentorship Excellence Award (2023-2024)** and the **Ian Rabinowitz Award for Teaching Excellence (2020-2021)** for her support of the UNMCCC Hematology and Oncology Fellowship. She was also honored with the **George and Sarah Jane Fisher Young Investigator Award (2017)** for her contributions to clinical research.

MEMO

To: Cinnamon Blair
Chair, UNM Naming Committee

From: Dr. Yolanda Sanchez
Maurice and Marguerite Liberman Distinguished Chair in Cancer Research
Director & CEO, UNM Comprehensive Cancer Center

Date: January 30, 2024

Re: **Creation of the Peter A. Winograd Endowed Clinical Research Professorship and Appointment of Dr. Neda Hashemi as the inaugural holder.**

Dear Ms. Blair and members of the naming committee,

On behalf of the UNM Comprehensive Cancer Center (UNMCCC) we would like to request approval to create the Peter A. Winograd Endowed Clinical Research Professorship. This naming request is respectfully submitted in accordance with UNM Administrative Policy 1020: Naming Facilities, Spaces, Endowments, and Programs, under Section 2.2.

Peter A. Winograd is a 46-year cancer survivor and was treated for melanoma at the UNM Comprehensive Cancer Center by Dr. John H. Saiki. He considers his years of survival to be "borrowed time," and has tried to make the most of them. He is a Professor Emeritus at the University of New Mexico School of Law. He joined the UNM law faculty as associate dean in 1976 and became a tenured professor in 1981. Over the years, Peter Winograd has played significant roles in a number of national associations, including the Law School Admission Council, the Association of American Law Schools, and the American Bar Association. He is an elected life member of the American Law Institute. He has chaired or been a member of more than 30 law school site evaluation teams across the country as part of his ABA work. He was a member of the Council of the ABA's Section of Legal Education and Admissions to the Bar (the recognized accrediting agency for U.S. law schools) from 2000 to 2009, including four years as Secretary. He received the prestigious Robert J. Kutak Award from the Legal Education Section in 1999 for "significant contributions toward increased cooperation between legal education, the practicing bar, and the judiciary." His service to the ABA has also included membership on the Board of Governors from 2010 to 2013, and service as a Section Officers Conference Liaison to the Board from 2013 to 2017. Peter Winograd earned degrees from Brown University (B.A., 1960), Harvard Law School (J.D., 1963), and New York University School of Law (LL.M., 1965). He has been admitted to the Bar in New Mexico and the District of Columbia. Before coming to UNM, he had been Assistant Dean at NYU School of Law,

Associate Dean at Georgetown University Law Center, and a Division Director at the Educational Testing Service.

Additionally, as prescribed by Faculty Handbook Policy C170 “Endowed Chairs and Named Professorships”, we seek approval to appoint Neda Hashemi, MD. Dr. Hashemi will be the first holder of this newly endowed professorship.

Dr. Hashemi completed her residency at the University of Texas in Houston and her fellowship at Indiana University. In her distinguished career, she has received many awards and honors. Most recently, she was awarded the National Cancer Institute Early Career Cancer Clinical Investigator Award (NCI ECIA) in 2024 and had been nominated for ASCO Leadership Program by the UNMCCC leadership. She currently serves as an Associate Professor and full member of the UNMCCC, where she holds key leadership positions, including Leader of the Genitourinary (GU) Clinical Working Group, Chair of the Protocol Review and Monitoring Committee (PRMC), and Medical Director of the New Mexico Cancer Research Alliance (NMCRA).

As a medical oncologist and leader of the GU Clinical Working Group at UNMCCC, Dr. Hashemi is committed to improving outcomes for patients with GU cancers through clinical research and expanded access to trials, particularly for underserved populations. She has successfully built a multidisciplinary collaboration with urologic and radiation oncology teams, enhancing the clinical trial portfolio with a balanced mix of NCI-sponsored (NCTN), industry, and investigator-initiated studies. She has served as a principal investigator and co-investigator on numerous trials conducted through NRG Oncology, SWOG, ECOG, and the Alliance for Clinical Trials in Oncology. Additionally, she is the NCI Community Oncology Research Program (NCORP) representative for the NCI GU Cancers Steering Committee (GUSC) Prostate Cancer Task Force, a member of the GU Working Group of the Hoosier Cancer Research Network (HCRN), and a member of the Immuno-Oncology Committee of the Alliance for Clinical Trials in Oncology.

Dr. Hashemi is also dedicated to mentoring the next generation of oncologists. Her contributions to education and mentorship have been recognized with several prestigious awards, including the Research Mentorship Excellence Award (2023-2024) and the Ian Rabinowitz Award for Teaching Excellence (2020-2021) for her support of the UNMCCC Hematology and Oncology Fellowship. She was also honored with the George and Sarah Jane Fisher Young Investigator Award (2017) for her contributions to clinical research.

For your consideration, we have included Dr. Neda Hashemi’s CV and letters of support for your review. Thank you for your time and consideration of this request.

January 31st, 2025

To: Ms. Cinnamon Blair
Chair of UNM Naming Committee
Chief Marketing and Communications Officer

Re: Appointment of Dr. Neda Hashemi as the **Peter A. Winograd Endowed Professor in Clinical Research**

Dear Ms. Blair,

It is my distinct pleasure to nominate Dr. Neda Hashemi for consideration as the recipient of the **Peter A. Winograd Endowed Professor in Clinical Research**. Dr. Hashemi is the Leader of the Genitourinary (GU) Clinical Working Group at the University of New Mexico Comprehensive Cancer Center (UNMCCC). As the Director and CEO of the UNMCCC, I have had the privilege of working closely with Dr. Hashemi and have witnessed her transformative impact on cancer care and research. Her exceptional achievements, leadership, and commitment to addressing healthcare disparities make her an exemplary candidate for this prestigious honor.

Dr. Hashemi is dedicated to improving outcomes for patients with GU cancers, particularly those from underserved communities. Since assuming leadership of the GU Oncology Clinical Working Group in 2020, she has expanded GU oncology services and research, playing a pivotal role in UNMCCC's successful renewal of its National Cancer Institute (NCI) Comprehensive Cancer Center designation in 2021. She has served as site principal investigator for 26 clinical trials since 2018, enrolling over 95 patients—more than 50% from racial and ethnic minority backgrounds, including 37% Hispanic/Latinx, 11% American Indian, and 2.5% Asian patients - populations often underrepresented in clinical research. Her leadership has created a model of multidisciplinary collaboration, establishing biweekly GU Tumor Boards and a streamlined referral process that integrates clinical trial screening and nurse navigation from the start of patient care. She has worked to simplify and optimize the enrollment process for GU cancer trials at UNMCCC and across the New Mexico Cancer Research Alliance (NMCRA) consortium, which is our state-wide clinical trials network. As Medical Director of NMCRA, she oversees clinical trial operations across multiple sites, expanding access to cutting-edge treatments for New Mexico's diverse population.

Dr. Hashemi's contributions have earned national recognition. She was awarded the NCI Early Career Cancer Clinical Investigator Award (ECIA) in 2024, underscoring her commitment to increasing minority participation in National Clinical Trials Network (NCTN) studies and her growing national reputation as a leader in cancer clinical research. Her leadership extends to addressing disparities in renal cell carcinoma (RCC) care through the NCI U2C CA252973-01 PE-CGS project, "Engagement of American

Indians of Southwestern Tribal Nations in Cancer Genome Sequencing,” exemplifying her dedication to using research to promote health equity.

Dr. Hashemi’s influence extends to national leadership roles. She serves as the NCI Community Oncology Research Program (NCORP) representative for the NCI Genitourinary Cancers Steering Committee (GUSC) Prostate Cancer Task Force, where she has championed the inclusion of underrepresented populations in clinical trials. Additionally, since 2023, she has chaired the Protocol Review and Monitoring Committee (PRMC) at UNMCCC, ensuring the scientific rigor and feasibility of all clinical trials conducted at the center.

In recognition of her extraordinary achievements and leadership potential, Dr. Hashemi was unanimously designated as an Emerging Leader at UNMCCC in 2024. This designation reflects her colleagues’ and institution’s confidence in her ability to shape the future of cancer care and research. She has already participated in leadership development workshops, where her insights and collaborative spirit have earned the admiration of her peers.

In summary, Dr. Hashemi exemplifies the qualities of an endowed professor—excellence in research, leadership, and a deep commitment to equitable cancer care. Her contributions have transformed oncology in New Mexico and set a benchmark for innovation and inclusivity. I am honored to nominate her for this prestigious recognition, confident that she will continue making groundbreaking contributions as an endowed professor in research.

Respectfully,



Dr. Yolanda Sanchez, PhD
The Maurice and Marguerite Liberman Distinguished Chair in Cancer Research
Professor, Department of Internal Medicine
Director & CEO, University of New Mexico Comprehensive Cancer Center

January 28th, 2025

To: Ms. Cinnamon Blair
Chair of UNM Naming Committee
Chief Marketing and Communications Officer

Re: Appointment of Dr. Neda Hashemi as the **Peter A. Winograd Endowed Professor in Clinical Research**

Dear Ms. Blair,

I am pleased to offer my strongest support for the nomination of Dr. Neda Hashemi Sadraei for the **Peter A. Winograd Endowed Professorship in Clinical Research** in recognition of her extraordinary accomplishments, impactful leadership, and unwavering dedication to advancing clinical research. Dr. Hashemi is a cornerstone of the University of New Mexico Comprehensive Cancer Center (UNMCCC), and her contributions have elevated the national and local profile of our institution. As Chief of the Division of Hematology and Oncology and her mentor since she joined us in 2018, I have witnessed firsthand her remarkable trajectory as a clinical researcher, leader, and advocate for equitable cancer care.

Dr. Hashemi came to us with a strong academic background. After earning her medical degree, she pursued a clinical research fellowship in Neuro-Oncology at the Cleveland Clinic Brain Tumor & Neuro-Oncology Center, successfully completing it in 2012. She then completed her Internal Medicine residency at the University of Texas Health Science Center at Houston, where she conducted clinical research at MD Anderson Cancer Center and graduated as the Outstanding Resident of the Year in 2015. She subsequently completed her Hematology/Oncology fellowship at Indiana University, serving as chief fellow (program of 15 fellows) in 2017-2018. As a senior fellow, she was selected for the competitive and prestigious 2018 American Society of Clinical Oncology/American Association of Cancer Research (ASCO/AACR) Vail Workshop on clinical trial design. She joined UNMCCC with a sound fundamental understanding of clinical trial design as well as of the necessary infrastructure to lead a large clinical trials menu at an academic center and was early on recognized as a faculty member with extraordinary leadership potential. She currently holds the rank of associate professor, and her exceptional contributions have earned her numerous accolades, including nomination for the ASCO Leadership Development Program, appointment as Chair of the Protocol Review and Monitoring Committee (PRMC), and formal recognition as an Emerging Cancer Center Leader in 2024.

Dr. Hashemi was entrusted with leading the Genitourinary (GU) Oncology Clinical Working Group in 2020, shortly after joining UNMCCC. Despite the challenges posed by the COVID-19 pandemic, she successfully built a multidisciplinary team integrating urologic oncology, radiation oncology, and medical oncology. Under her leadership, the GU oncology program has expanded its clinical trial portfolio, and her ability to foster collaboration has made the GU team a model for clinical research excellence. Dr. Hashemi's efforts have yielded remarkable results, with a

significant increase in enrollments in GU oncology clinical trials since the beginning of 2023, surpassing the numbers seen in the same period in the past years. Her team has been the highest enrolling in treatment trials at UNMCCC for two consecutive years (2023 and 2024). Her groundbreaking work earned her the National Cancer Institute (NCI) Early Career Cancer Clinical Investigator Award (ECIA) in 2024, further solidifying her impact on promoting inclusivity in clinical research. Dr. Hashemi's impact extends beyond UNMCCC. She has taken on national leadership roles, including serving on the NCI Genitourinary Cancers Steering Committee's Prostate Cancer Task Force, where she advocates for diversity and inclusivity in clinical trials.

Beyond her research achievements, Dr. Hashemi is an exceptional mentor. She has guided numerous faculty and trainees, fostering the next generation of clinical investigators. Her mentees have presented at national meetings, published in high-impact journals, and assumed leadership roles in clinical trials. Her mentorship excellence was recognized with the UNMCCC Mentorship Excellence Award in 2024. Under her guidance, junior faculty members have achieved significant milestones, such as site principal investigator designations and clinical trial leadership roles.

Dr. Hashemi has also played a pivotal role in optimizing clinical trial operations at UNMCCC. As Chair of PRMC, she oversees the scientific review of all clinical trials, ensuring rigor and feasibility. She has spearheaded quality improvement initiatives, including efforts to enhance adherence to oral oncolytic therapy and reduce outpatient infusion wait times, significantly improving patient outcomes and operational efficiency. She was also instrumental in developing the prostate cancer theranostics program at UNMCCC. Under her leadership, Prostate-Specific Membrane Antigen (PSMA) imaging was introduced in 2022, followed by PSMA radioligand therapy in 2023, first through clinical trials and later as standard-of-care treatment. Her forward-thinking vision and commitment to innovation have positioned UNMCCC at the forefront of theranostics. As the center expands its theranostics program, projected to be fully operational by 2026, Dr. Hashemi's expertise in building multidisciplinary collaborations will be invaluable in leading this effort.

In recognition of her exceptional accomplishments and leadership potential, Dr. Hashemi was named an Emerging Leader at UNMCCC in 2024, reflecting our confidence in her ability to advance the cancer center's mission.

In summary, Dr. Hashemi exemplifies the qualities of a visionary leader, dedicated mentor, and transformative researcher. Her ability to drive impactful change, foster collaboration, and mentor the next generation of investigators makes her an ideal candidate for this endowed professorship. She has my highest recommendation and the full support of the UNMCCC leadership as she continues to build on her outstanding record of achievements.

Sincerely,



Zoneddy Dayao, MD
Chief, Division of Hematology and Oncology
University of New Mexico Comprehensive Cancer Center

CURRICULUM VITAE

Date January 15, 2025

Name Neda Hashemi Sadraei, M.D.

Professional Address University of New Mexico Comprehensive Cancer Center
1 University of New Mexico, MSC 07-4025,
Albuquerque, NM 87131-0001
Phone: (505) 925-0421
Fax: (505) 925-0408
E-mail: nhashemi@salud.unm.edu

Medical Licensures

2018 - Present State of New Mexico (License #2018-0028)
2015 - 2018 State of Indiana (License #01075459A)

Certifications

2024 Board certified in Hematology (ABIM ID: 356211)
2018 Board certified in Medical Oncology (ABIM ID: 356211)
2015 Board certified in Internal Medicine (ABIM ID: 356211)
2011 Certificate of Educational Commission for Foreign Medical Graduates (ECFMG certification) (ECFMG ID: 0-730-610-3)

Educational History

Jul 2017 – Jun 2018 Chief Fellow
Hematology/Oncology Fellowship Program, Indiana University, Indianapolis, IN
Jul 2015 – June 2018 Hematology/Oncology Fellow
Indiana University, Indianapolis, IN
Aug 2012 – Jul 2015 Internal Medicine Resident (internship and residency)
University of Texas Health Science Center at Houston, Houston, TX
Aug 2010 – Jun 2012 Neuro-Oncology Research Fellow
The Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Neurological Institute,
Cleveland Clinic Foundation, Cleveland, OH
Dec 2008 – Nov 2009 Pulmonary Research Fellow
National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Tehran, Iran
Jan 1996 – Aug 2003 Iran University of Medical Sciences (IUMS)
Doctor of Medicine
Continuous program including 18 months of internship
Tehran, Iran

Employment History

July 2024 – present Associate Professor of Medicine, Division of Hematology/Oncology
University of New Mexico Comprehensive Cancer Center,
Albuquerque, NM
2018 – 2024 Assistant Professor of Medicine, Division of Hematology/Oncology
University of New Mexico Comprehensive Cancer Center,
Albuquerque, NM

Employment History (continued)

- Apr 2006 – Nov 2009 Primary Care Physician
Shafa Medical Center, Tehran, Iran
- Apr 2004 – Mar 2007 Medical Advisor and Product Specialist
Actover Pharmaceutical Company (agent of Pfizer, Actavis), Tehran, Iran
- Prepare educational material for target physicians
 - Conduct regional talks
- Nov 2003 – Mar 2006 Principal Coordinator and Lead Investigator
National Department of Disease Prevention, Iran State Welfare Organization, Tehran, Iran
- Prevention of landmine disabilities
 - National preschool vision screening for amblyopia

Honors/Awards

- 2024 Research Mentorship Excellence Award 2023-2024, for the support of the Hematology and Oncology ACGME fellowship for University of New Mexico Comprehensive Cancer Center, Albuquerque, NM
- 2021 Ian Rabinowitz Award for Teaching Excellence 2020-2021, for the support of the Hematology and Oncology ACGME fellowship for University of New Mexico Comprehensive Cancer Center, Albuquerque, NM
- 2018 Selected participant for AACR/ASCO Vail Methods in Clinical Cancer Research Workshop, Vail, Colorado
- 2017 George and Sarah Jane Fisher Young Investigator Award
A \$15,000 research grant awarded by Hoosier Cancer Research Network (HCRN), Indianapolis, IN
- 2015 Outstanding Graduating Resident of the Year, 2014-2015 (class of 36)
University of Texas Health Science Center at Houston, Houston, TX
- 2011 Second Place Award, Associate Research Category Poster Competition
American College of Physicians (ACP) Ohio Chapter Meeting, Columbus, OH
- 2006 Employee of the Year
Actover Pharmaceutical Company, Tehran, Iran

Workshops/Additional Training

- Jun 2024 Emerging Leaders Workshop: Changing the Face of Leadership
University of New Mexico and University of Southern California Norris Comprehensive cancer Centers, Jun 10-12, 2024, Albuquerque, NM
- Jun 2023 Reaching for Equitable Access for Latinos (REAL) Workshop: addressing challenges of Hispanic/Latino inclusion in trials, US Medical and BMS Organization for Latino Achievement (OLA), Chicago, IL
- Feb 2023 Integrating Online and In-person Training
University of New Mexico, Albuquerque, NM
- Jan 2023 Learning Peer Observation in Support of Effective Teaching-POSET
University of New Mexico, e-learning
- Dec 2022 Advancing Inclusive Teaching and Learning
University of New Mexico, Albuquerque, NM
- Dec 2022 Teaching with Limited Time While Providing Patient Care in the Outpatient Setting
University of New Mexico, e-learning

Nov 2022	Providing Feedback and Evaluating Learners University of New Mexico, e-learning
Sep-Oct 2022	Design and Management of Cancer Clinical Trials University of Miami Leonard M Miller School of Medicine, online live course
Jul 2018	AACR/ASCO Methods in Clinical Cancer Research American Association for Cancer Research (AACR) / American Society of Clinical Oncology (ASCO), Vail, Colorado
Jun 2018	Grant Writing American Society of Clinical Oncology (ASCO), Chicago, IL
Jun 2018	Annual Fellows Forum in Breast Oncology Physicians Learning and Teaching in Oncology (PLATO) Foundation, Chicago, IL
Nov 2017	Stanford Faculty Development Program on Clinical Teaching Indiana University, Indianapolis, IN
Nov 2017	Biostatistics Workshop for Healthcare Researchers Indiana University Purdue University, Indianapolis, IN
Jun 2017	Annual Fellows Forum in Breast Oncology Physicians Learning and Teaching in Oncology (PLATO) Foundation, Chicago, IL
Oct 2016	Foundational Research Workshop Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Mar 2016	Oncotalk: Workshop for Building Oncologists' Communication Skills Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Memberships in Professional Societies

Apr 2016 - Present	Member, American Association for Cancer Research (AACR)
Jul 2015 - Present	Member, American Society of Clinical Oncology (ASCO)
Jul 2015 – July 2019	Member, American Society of Hematology (ASH)
Apr 2011 – Jul 2015	Member, American College of Physicians (ACP)

Invited Lectures/Talks

1. Speaker, University of New Mexico Comprehensive Cancer Center Hematology/Oncology Grand Rounds, "Molecular Tumor Board, Clinicopathologic and Genomic Integration: a case of fumarate hydratase predisposition syndrome", Albuquerque, NM, November 15, 2024.
2. Invited Section Chair and Moderator, Santa Fe Precision Oncology Symposium, "Managing Toxicities of Oral Oncolytics and ADCs", Santa Fe, NM, October 19, 2024
3. Invited Speaker, 28th Annual Innovations in Urologic Practice, "Updates in Advanced Urothelial Carcinoma", Albuquerque, NM, September 20-22, 2024
4. Invited Speaker, Best of ASCO 2024, "Updates in Prostate Cancer Theranostics", Albuquerque, NM, June 22-23, 2024
5. Invited Speaker, Best of ASCO 2024, "Updates in Bladder Cancer", Albuquerque, NM, June 22-23, 2024
6. Community Oncology Working Group (COWG), "ESMO 2023 Genitourinary Highlights", November 15, 2023
7. Invited Speaker, Prostate Cancer Support Association of New Mexico Annual Conference, "Management of Advanced Prostate Cancer", Albuquerque, NM, November 4, 2023
8. Invited Speaker, Santa Fe Precision Oncology Symposium, "Precision Oncology in Genitourinary Cancers", Santa Fe, NM, October 21, 2023
9. Invited Panelist/Moderator, Santa Fe Precision Oncology Symposium, Precision Oncology - Case Discussion in Genitourinary Cancers", Santa Fe, NM, October 21, 2023

10. New Mexico Cancer Research Alliance Scientific Retreat, "Genitourinary Cancers ASCO 2023 Updates and Trial Menu Highlights", Albuquerque, NM, June 21, 2023.
11. Invited Speaker, Rocky Mountain Urologic Society (RMUS) 2023 Annual Spring Meeting, "Systemic Therapy in Kidney Cancer", Denver, Colorado, April 14, 2023
12. Invited Panelist, Rocky Mountain Urologic Society (RMUS) 2023 Annual Spring Meeting, "Challenging Cases in Kidney Cancer", Denver, Colorado, April 14, 2023
13. Invited Speaker, Urology Grand Rounds, University of New Mexico, "Unclear decisions in Clear Cell Renal Cell Carcinoma", Albuquerque, NM, Oct 21, 2022
14. Invited Speaker, Prostate Cancer Support Association of New Mexico Annual Conference, "Treatment of metastatic prostate cancer", Albuquerque, NM, November 6, 2021
15. Speaker, University of New Mexico School of Medicine Internal Medicine Grand Rounds, "Testicular Cancer: A Journey to Cure", Albuquerque, NM, October 8, 2020
16. Invited Speaker, Prostate Cancer Support Association of New Mexico, "Combination therapies in prostate cancer", Albuquerque, NM, August 15, 2020
17. Invited Speaker, Prostate Cancer Support Association of New Mexico, "Future therapies in prostate cancer", Albuquerque, NM, March 2, 2019
18. Speaker, Indiana University Melvin & Bren Simon Cancer Center Grand Rounds, "Escaping the Black Hole - Improving Communication with Referring Physicians", Indianapolis, IN, May 2018.
19. Invited Speaker, University of New Mexico Comprehensive Cancer Center, "Metastatic bladder cancer: Past, Present, and Future", Albuquerque, NM, July 27, 2017.

Scholarly Achievements

Original Research or Scholarly Articles in Refereed Journals

1. **Hashemi-Sadraei N**, Riahi T, Masjedi MR: Idiopathic Pulmonary Fibrosis in Iran: are patients developing the disease at a younger age? *Arch of Iran Med*. 2013 Mar;16(3):177-81
2. Rahmathulla G, Hovey H, **Hashemi-Sadraei N**, Ahluwalia MS. Bevacizumab in high grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. *Onco Targets Ther*. 2013 Apr 15;6:371-89.
3. **Hashemi-Sadraei N**, Dahiya S, Chao ST, Murphy ES, Osei-Boateng K, Xie H, Suh JH, Peereboom DM, Stevens GH, Ahluwalia MS. Treatment of Cerebral Radiation Necrosis with Bevacizumab: The Cleveland Clinic Experience. *Am J Clin Oncol*. 2013 Jun 24.
4. **Hashemi-Sadraei N**, Machicado J, Gupta R, Huapaya J. Lactic acidosis in gastric cancer. *J Gastrointest Cancer*. 2014 Jun 1.
5. **Hashemi-Sadraei N**, Gupta R, Machicado J, Govindu R. Bilateral acromioclavicular septic arthritis as an initial presentation of Streptococcus pneumoniae endocarditis. *Case Rep Infect Dis*. 2014 Jun.
6. **Hashemi-Sadraei N**, Vejpongsa P, Baljevic M, Chen L, Idowu M. Epstein-barr virus-related hemophagocytic lymphohistiocytosis: hematologic emergency in the critical care setting. *Case Rep hemtol*. 2015 Jan.
7. Gupta R, **Hashemi-Sadraei N**, Jay C, Ramesh N, Song J, Lei X, Rose EJ, Carter K, Araujo DM, Benjamin RS, Patel S, Nates JL, Ravi V. Predictors of survival in patients with sarcoma admitted to the intensive care unit. *Clin Sarcoma Res*. 2016 Jul 19;6:12.
8. McCleskey BC, Epstein JI, Albany C, **Hashemi-Sadraei N**, Idrees MT, Jorns JM, Lu DY, Matoso A, Rais-Bahrami S, Schwartz LE, Ulbright TM, Gordetsky J. The Significance of Lymphovascular Invasion of the Spermatic Cord in the Absence of Cord Soft Tissue Invasion. *Arch Pathol Lab Med*. 2017 Jun;141(6):824-829.
9. **Hashemi-Sadraei N**, Hanna, N. Targeting FGFR in squamous cell carcinoma of the lung. *Target Oncol*. 2017 Dec;12(6):741-755
10. **Hashemi-Sadraei N**, Gbolahan OB, Salfity H, O'Neil B, House MG, Shahda S. Clinical Characteristics of Patients Experiencing Pathologic Complete Response following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. *Am J Clin Oncol*. 2018 Oct;41(10):982-985.
11. Gordetsky J, Sanfrancesco J, Epstein JI, Trevino K, Xu H, Osunkoya A, Xiao GQ, Kao CS, Unger P, **Hashemi-Sadraei N**, Albany C, Jorns JM, Lu DY, Matoso A, Rais-Bahrami S, Schwartz LE, Ulbright TM, Idrees MT. Do Nonseminomatous Germ Cell Tumors of the Testis With Lymphovascular Invasion of the Spermatic Cord Merit Staging as pT3? *Am J Surg Pathol*. 2017 Oct;41(10):1397-1402.
12. Perrino CM, Eble J, Kao CS, Whaley RD, Cheng L, Idrees M, **Hashemi-Sadraei N**, Monn MF, Kaimakliotis HZ, Bandali E, Grignon D. Plasmacytoid/diffuse urothelial carcinoma: a single institution immunohistochemical and molecular study of 69 patients. *Hum Pathol*. 2019 Aug;90:27-36.
13. Gbolahan O, **Hashemi-Sadraei N**, O'Neil B. Prolonged Response to Anti-PD1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma with High Tumor Mutational Burden. *J Natl Compr Canc Netw*, 2019 Jun 1;17(6):644-648.
14. Bowles H, Tawfik B, Abernathy J, Lauer R. **Hashemi-Sadraei N**, Dayao Z. Pharmacist-Driven Oral Oncolytic Medication Education and Consent. *JCO Oncol Pract*. 2020 Oct;16(10):e1209-e1215.
15. **Hashemi-Sadraei N**, Sasankan S, Crozier N, Tawfik B, Kittson R, Abernathy J, Lauer R, Dayao Z. Improving Outpatient Infusion Clinic Wait Times at a Comprehensive Cancer Center. *JCO Oncol Pract*. 2021 Dec;17(12):e1935-e1942.
16. Sharma H, Franklin M, Braunberger R, **Hashemi-Sadraei N**. Cutaneous Metastasis from Prostate Cancer: A Case Report with Literature Review. *Current Problems in Cancer: Case Reports*. 7(2022)100175.

17. Gbolahan O, **Hashemi-Sadraei N**, Yash S, Williams G, Ramachandran R, Kim Y, Paluti R, Outlaw D, El-rayes B, Nabell L. Time to treatment initiation and its impact on real-world survival in metastatic colorectal cancer and pancreatic cancer. *Cancer Med*, 2023 Feb;12(3):3488-3498.
18. Sharma, H.; Moturi, RK; Pankratz, V.S.; Yilmaz, E; Gbolahan, O; Kumar, A; **Hashemi-Sadraei, N**. Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after a minimum of twelve months. *J Cancer Res Clin Onco*, 2023 Apr 28;1-8.
19. Moturi K, Sharma H, **Hashemi-Sadraei N**. Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management. *Int J Mol Sci*, 2023 Dec 28;25(1):414.
20. Faber LS, Hodges H, **Hashemi-Sadraei N**, Alba F. Duodenal duplication cyst masquerading as metastatic nonseminomatous germ cell tumor. *JU Open Plus* 2024 Mar 2(3)

Works in Progress

In preparation

1. Pembrolizumab-induced myelopathy vs acute inflammatory demyelinating polyneuropathy (AIDP) vs chronic inflammatory demyelinating polyneuropathy (A-CIDP) – manuscript in progress
2. Diagnosis of chronic kidney disease etiology through workup of Immune checkpoint inhibitor-induced renal toxicity: a case report and review of the mechanisms of renal injury –manuscript in progress
3. Racial and Ethnic Disparities in Metabolic Syndrome Risk Factor Screening Among Prostate Cancer Patients Treated with Androgen Deprivation Therapy –manuscript in progress
4. Longitudinal Trends in Metabolic Syndrome Risk Factor Screening and Treatment Among Prostate Cancer Patients Treated with Androgen Deprivation Therapy –manuscript in progress

Oral Presentations at Professional Meetings

1. An introduction to motor disabilities. **Hashemi-Sadraei N**, National Workshop on Preventing Motor Disabilities, State Welfare Organization, Tehran, Iran, May 1, 2005.
2. Glioblastoma in the elderly: The Cleveland Clinic Experience (1991-2010). **Hashemi-Sadraei N**, Neurological Institute Research Day, Cleveland Clinic, Cleveland, OH, May 26, 2011.
3. Stereotactic radiosurgery of brain metastases in elderly patients: the Cleveland Clinic Experience. Ahluwalia M, **Hashemi-Sadraei N**, Suh J, Chao S, Angelov L, Weil R, Vogelbaum M, Elson P, Barnett G, 16th International Leksell Gamma Knife Society Meeting, Sydney, Australia, March, 2012.
4. Bevacizumab therapy for cerebral radiation necrosis. **Hashemi-Sadraei N**, Neurological Institute Research Day, Cleveland Clinic, Cleveland, OH, May 24, 2012.

Refereed Posters/Published Abstracts (International/National/Regional Conferences)

1. **Hashemi-Sadraei N**, Yazdanparast T, Ghandizadeh S, Farshidi S, Hatamizadeh N. Epidemiology of Burns in Iran, a Cross-Sectional Study. Accepted for oral presentation at the 15th Conference of the International Society of Burn Injuries (ISBI), Istanbul, Turkey, June 21-25, 2010.
2. **Hashemi-Sadraei N**, Bawa HS, Satra A, Rahmathulla G, Patel M, Stevens G, Tekautz TM, Rybicki LA, Peereboom DM, Suh JH, Weil R, Vogelbaum MA, Barnett GH, Ahluwalia MS. Prognostic factors in patients with WHO grade III gliomas, The Cleveland Clinic experience. Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011, *J Clin Oncol*. May; 29 (15-suppl): 2053, 2011.
3. Bawa HS, **Hashemi-Sadraei N**, Suh JH, Stevens G, Rahmathulla G, Chao ST, Tekautz TM, Elson P, Peereboom DM, Angelov L, Weil R, Vogelbaum MA, Barnett GH, Ahluwalia MS. Glioblastoma in the elderly: The Cleveland Clinic experience (1992-2010). Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011, *J Clin Oncol*. May; 29 (15-suppl): 2066, 2011.

4. Satra A, **Hashemi-Sadraei N**, Bawa HS, Peereboom DM, Stevens G, Rybicki LA, Suh JH, Vogelbaum MA, Weil R, Barnett GH, Ahluwalia MS. Prognostic factors in elderly patients with grade III gliomas. Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011, *J Clin Oncol*. May; 29 (15-suppl): 2093, 2011.
5. **Hashemi-Sadraei N**, Patel M, Rahmathulla G, Recinos P, Chao ST, Stevens GH, Peereboom DM, Angelov L, Weil RJ, Vogelbaum MA, Suh JH, Barnett GH, Ahluwalia MS. Stereotactic radiosurgery in elderly patients with brain metastases. Accepted for poster presentation at the Second International Symposium on Long-Term Control of Metastases to the Brain and Spine; Cleveland, OH, September 9-10, 2011.
6. Ahluwalia MS, **Hashemi-Sadraei N**, Suh JH, Chao ST, Angelov L, Weil RJ, Vogelbaum MA, Elson P, Barnett GH. Stereotactic radiosurgery of brain metastases in elderly patients: the Cleveland Clinic experience. Poster presented at the European Society for Medical Oncology (ESMO), Stockholm, Sweden, September 23-27, 2011, *Eur J Cancer*. Sep; 47 (1-suppl): S276-7, 2011.
7. **Hashemi-Sadraei N**, Bawa HS, Elson P, Ahluwalia MS. Elevated glucose levels and survival in elderly patients with newly diagnosed glioblastoma. Poster presented at the Ohio American College of Physicians (ACP) Chapter meeting, Columbus, OH, October 14, 2011.
8. Ahluwalia MS, **Hashemi-Sadraei N**, Rahmathulla G, Patel M, Chao ST, Peereboom DM, Weil RJ, Suh JH, Vogelbaum MA, Stevens GH, Barnett GH. Treatment of cerebral radiation necrosis with Bevacizumab: The Cleveland Clinic experience. Poster presented at the 16th Annual Scientific Meeting & Education Day of the Society for Neuro-Oncology (SNO), Orange County, CA, November 17-20, 2011, *Neuro-Oncology*. Nov; 13 (3-suppl): 66, 2011.
9. **Hashemi-Sadraei N**, Bawa HS, Rahmathulla G, Patel M, Elson P, Stevens GH, Peereboom DM, Vogelbaum MA, Weil RJ, Barnett GH, Ahluwalia MS. Elevated glucose levels and survival in elderly patients with newly diagnosed glioblastoma. Poster presented at the 16th Annual Scientific Meeting & Education Day of the Society for Neuro-Oncology (SNO), Orange County, CA, November 17-20, 2011, *Neuro-Oncology*. Nov; 13 (3-suppl): 63-4, 2011.
10. Ahluwalia M, **Hashemi-Sadraei N**, Stevens G, Angelov L, Chao S, Suh J, Peereboom D, Weil R, Vogelbaum M, Barnett G. Glioblastoma in the Elderly: The Cleveland Clinic experience (1991-2010). Poster presented at the 15th Biennial Canadian Neuro-Oncology Meeting (CNO), Vancouver, BC, Canada, February 9-11, 2012, *Can J Neurol Sci*. Jan; 39 (1-suppl): S-22, 2012.
11. Ahluwalia M, **Hashemi-Sadraei N**, Peereboom D, Stevens G, Angelov L, Suh J, Vogelbaum M, Barnett G. WHO grade III gliomas. Poster presented at the 15th Biennial Canadian Neuro-Oncology Meeting (CNO), Vancouver, BC, Canada, February 9-11, 2012. *Can J Neurol Sci*. Jan; 39 (1-suppl): S22, 2012.
12. Stevens GH, **Hashemi-Sadraei N**, Elson P, Ahluwalia MS. Elevated preoperative glucose levels and survival in elderly newly diagnosed glioblastoma patients. Poster presented at the 15th Biennial Canadian Neuro-Oncology Meeting (CNO), Vancouver, BC, Canada, February 9-11, 2012, *Can J Neurol Sci*. Jan; 39 (1-suppl): S17, 2012.
13. Patel M, **Hashemi-Sadraei N**, Elson P, Singh Ahluwalia MS. Prognostic nomogram in elderly patients with glioblastoma. Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012. *J Clin Oncol*. May; 30 (15-suppl): 2096, 2012.
14. Robles Irizarry L, Fawole AA, **Hashemi-Sadraei N**, Patel M, Elson P, Tekautz TM, Murphy ES, Recinos V, Chao ST, Suh JH, Peereboom DM, Stevens G, Weil RJ, Vogelbaum MA, Barnett GH, Ahluwalia MS. Adult low grade gliomas: The Cleveland Clinic experience. Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012. *J Clin Oncol*. May; 30 (15-suppl): 2076, 2012.
15. Fawole AA, Robles Irizarry L, **Hashemi-Sadraei N**, Patel M, Ahluwalia MS. Low-grade gliomas in older patients. Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012. *J Clin Oncol*. May; 30 (15-suppl): 2093, 2012.

16. **Hashemi-Sadraei N**, Robles Irizarry L, Patel M, Tekautz TM, Murphy ES, Recinos V, Chao ST, Suh JH, Peereboom DM, Stevens G, Weil RJ, Vogelbaum MA, Barnett GH, Ahluwalia MS. Anaplastic oligodendroglial tumors: The Cleveland Clinic experience. Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012. *J Clin Oncol*. May; 30 (15-suppl): 2100, 2012.
17. **Hashemi-Sadraei N**, Machicado J. A Potentially Catastrophic Complication of Sickle Cell Disease. Poster presented at the American College of Physicians (ACP) Local Meeting, Houston, TX, March 23, 2013.
18. **Hashemi-Sadraei N**, Sharif S, Machicado J, Dahiya S, Ahluwalia MS. Risk factors for venous thromboembolism in elderly patients with glioblastoma. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, May 31-June 4, 2013, *J Clin Oncol* 31, 2013 (suppl; abstr e13031).
19. Gupta R, **Hashemi-Sadraei N**, Huapaya J. Lactic acidosis: not always tissue hypoxia. Poster presented at the American College of Physicians (ACP) Local Meeting, Galveston, TX, March 22, 2014.
20. Machicado J, **Hashemi-Sadraei N**, Gupta R. A hearty joint. Poster presented at the American College of Physicians (ACP) Local Meeting, Galveston, TX, March 22, 2014.
21. Jana T, Machicado J, Batra S, **Hashemi-Sadraei N**, Sushovan Guha S. In-hospital outcomes in patients with malignancy admitted for acute pancreatitis. Poster presented at the Annual meeting of the American College of Gastroenterology, Philadelphia, PA, October 17-22, 2014.
22. **Hashemi-Sadraei N**, Machicado J, Dierksen J. An uncommon initial manifestation of cancer. Poster presented at the American College of Physicians (ACP) Chapter meeting, Houston, TX, November 15-16, 2014.
23. Dehghani M, Gonzalez AO, **Hashemi-Sadraei N**, Zhang S, Rosenblatt KP. Correlation between germline and tumor CYP450 2D6 gene polymorphisms. Poster presented at the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, December 9-13, 2014.
24. Shah AY, Campbell MT, Nautiyal KD, **Hashemi-Sadraei N**, Matin SF, Wang X, Vaporciyan AA, Rhines LD, Moon BS, Lewis VO, Lin PP, Prabhu SS, Rao G, Corn PG, Pagliaro LC, Mehran RJ, Wood CG, Jonasch E, Tannir NM. Long-term survivorship in patients with metastatic renal cell cancer managed with metastasectomy: A retrospective study from the MD Anderson Cancer Center. Poster presented at the American Society of Clinical Oncology (ASCO)-Genitourinary Cancers Symposium (GU-ASCO), Orlando, FL, February 26-28, 2015. *J Clin Oncol* 33, 2015 (suppl 7; abstr 504)
25. Campbell MT, Shah AY, Nautiyal KD, **Hashemi-Sadraei N**, Corn PG, Pagliaro LC, Jonasch E, Tannir NM. Association of chronic co-morbidities with long term survival with metastatic renal cell carcinoma. Poster presented at the American Society of Clinical Oncology (ASCO)-Genitourinary Cancers Symposium (GU-ASCO), Orlando, FL, February 26-28, 2015. *J Clin Oncol* 33, 2015 (suppl 7; abstr 472)
26. Campbell MT, Shah AY, **Hashemi-Sadraei N**, Nautiyal KD, Corn PG, Pagliaro LC, Jonasch E, Tannir NM. Long-term survivorship in patients with metastatic renal cell cancer: A retrospective study from the MD Anderson Cancer Center. Poster presented at the American Society of Clinical Oncology (ASCO)-Genitourinary Cancers Symposium (GU-ASCO), Orlando, FL, February 26-28, 2015. *J Clin Oncol* 33, 2015 (suppl 7; abstr 510)
27. Mallesara Sudhakar S, **Hashemi-Sadraei N**, Manlapaz M, Yang MY, Varghese J. Adrenal Insufficiency Leading to Diagnosis of Metastatic Cancer. Poster presented at the Endocrine Society's 97th Annual Meeting and Expo (ENDO 2015), San Diego, CA, March 5-8, 2015.
28. Gonzalez A, Sathyan P, **Hashemi-Sadraei N**, Wachtler C, Zhang S, Dehghani M, Rosenblatt KP. Value of CYP2D6 genotyping based on germline-tumor polymorphisms and The Cancer Genome Atlas Outcomes Data. Poster presented at the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, December 8-12, 2015.

29. **Hashemi-Sadraei N**, Salfity, O'Neil B, House MG, Shahda S. Pathologic complete response following neoadjuvant chemotherapy and stereotactic body radiation therapy for borderline resectable/unresectable pancreatic adenocarcinoma: The Indiana University Experience. Poster presented at the American Association for Cancer Research (AACR) - Pancreatic Cancer: Advances in Science and Clinical Care. Orlando, FL. May 12-15, 2016
30. **Hashemi-Sadraei N**, Perrino CM, Monn MF, Bandali E, Cheng L, Idrees M, Bihrlle R, Koch MO, Eble J, Kao C, Albany C, Pili R, Grignon DA, Kaimakliotis HZ. Plasmacytoid urothelial carcinoma: A clinicopathological study. Poster presented at the American Society of Clinical Oncology (ASCO)-Genitourinary Cancers Symposium (GU-ASCO), San Francisco, CA, February 8-10, 2018. *J Clin Oncol* 36, 2018 (suppl 6S; abstr 482)
31. Albany C, **Hashemi-Sadraei N**, Fang F, Lowder J, Einhorn E, Nephew K. Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients with platinum refractory germ cell tumors (GCT): a phase 1 study. Poster presented at the American Association for Cancer Research (AACR) Annual Meeting, Chicago, IL, April 14-18, 2018 (abst 1386).
32. **Hashemi-Sadraei N**, Perrino CM, M. Monn MF, Bandali B, Cheng L, Idrees M, Bihrlle R, Koch MO, Eble J, Kao C, Adra N, Pili R, Grignon DA, Kaimakliotis HZ, Albany C. Role of systemic therapy in plasmacytoid urothelial carcinoma. Poster presented at the IU Simon Cancer Center's annual Cancer Research Day, Indianapolis, IN, May 2-3 (abstr 109).
33. **Hashemi-Sadraei N**, Perrino CM, M. Monn MF, Bandali B, Cheng L, Idrees M, Bihrlle R, Koch MO, Eble J, Adra N, Pili R, Grignon DA, Kaimakliotis HZ, Albany C. Survival outcomes in plasmacytoid urothelial carcinoma: Results with contemporary systemic therapy. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1- 4, 2018. *J Clin Oncol* 36, 2018 (suppl; abstr e16525).
34. **Hashemi-Sadraei N**, Einhorn LH, Perkins S, J Spinella MJ, Fang F, Hanna NH, Nephew KP, Albany C. Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients (pts) with platinum-refractory germ cell tumors (GCT): Preliminary results from an open label phase 1b study. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1- 4, 2018. *J Clin Oncol* 36, 2018 (suppl; abstr e16545).
35. Gbolahan OB, **Hashemi-Sadraei N**, Conteh A, Kaimakliotis HZ, Storkus W, Pili R, Logan TF. Clinical features and survival outcomes in a prospective spontaneous regression (SR) protocol of renal cell carcinoma (RCC) and melanoma (M) patients. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1- 4, 2018. *J Clin Oncol* 36, 2018 (suppl; abstr e16585).
36. **Hashemi-Sadraei N**, Kalra M, Gbolahan OB, Betbadal AM, Grethlein S. Improving communication with referring oncologists (RO): Indiana University experience. Poster presented at the American Society of Clinical Oncology (ASCO) Quality Care Symposium, Phoenix, AZ, Sep 28-29, 2018. *J Clin Oncol* 36, 2018 (suppl 30; abstr 276).
37. **Hashemi-Sadraei N**, Adra N, Kessler KA, Idrees MT, Einhorn L, Boothman DA. NAD(P)H: quinone oxidoreductase (NQO1) and Catalase expression in Non-seminomatous Germ Cell Tumors. Poster presented at the American Society of Clinical Oncology (ASCO)-Genitourinary Cancers Symposium (GU-ASCO), San Francisco, CA, February 13-15, 2020.
38. Adra N, Hauke R, Kaimakliotis H, Gulati S, **Hashemi-Sadraei N**, Pili R. Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma HCRN GU17-295. Poster presented at the American Society of Clinical Oncology (ASCO)-Genitourinary Cancers Symposium (GU-ASCO), San Francisco, CA, February 13-15, 2020.
39. **Hashemi-Sadraei N**, Dayao, ZR, Sasankan S, Cox A, Peacock S, Abernathy J, Kittson R, Tawfik B, Crozier N, Lauer R. Optimizing infusion wait time: Redesigning medication order verification/approval at a comprehensive cancer center. American Society of Clinical Oncology (ASCO) Annual Meeting Virtual, May 29-31, 2020. *J Clin Oncol* 38, no.15_suppl (abstr e14042).
40. Webster BR, Ton-That MV, **Hashemi-Sadraei N**, Shah SK. Plant-based diet trends in oncology patients. American Society of Clinical Oncology (ASCO) Annual Meeting Virtual, May 29-31, 2020. *J Clin Oncol* 38, no.15_suppl (abstr e19224).

41. Menhorn T, Zarick-Jones A, Harari Turquie M, Sasankan S, **Hashemi-Sadraei N**, Dayao ZR, Lauer RC, Tawfik B, Bowles H, Crozier N. Oral oncolytic education and adherence monitoring in poor, rural and minority patients. American Society of Clinical Oncology (ASCO) Annual Meeting Virtual, May 29-31, 2020. *J Clin Oncol* 38, no.15_suppl (abstr e19212).
42. **Hashemi-Sadraei N**, Adra N, Kesler KA, Idrees MT, Boothman DA, Einhorn L. Tissue analysis of NAD(P)H: quinone oxidoreductase (NQO1) and catalase expression in patients with germ cell tumors (GCT). Poster presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, June 22-23, 2020. *Cancer Res* 2020;80(16 Suppl) (abstr 5169)
43. Gbolahan O, Outlaw DA, **Hashemi-Sadraei N**, Paluri RV, Williams GR. Impact of time to treatment initiation on real-world (RW) outcomes in metastatic colorectal cancer (mCRC) in the United States. Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Virtual, June 4-8, 2021. *J Clin Oncol* 39, 2021 (suppl 15; abstr 3595).
44. Gbolahan O, Outlaw DA, **Hashemi-Sadraei N**, Paluri RV, Williams GR. Impact of time to treatment initiation on real-world (RW) outcomes in metastatic pancreatic cancer (mPC) in the United States. American Society of Clinical Oncology (ASCO) Annual Meeting Virtual, June 4-8, 2021. *J Clin Oncol* 39, 2021 (suppl 15; abstr e16254).
45. Sharma H, Moturi KR, Yilmaz E, Gbolahan O, Kumar A, **Hashemi-Sadraei N**. Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control. Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2022. *J Clin Oncol.* 40, 2022 (16_suppl; abstr 2586).
46. Brown J, Kaimakliotis HZ, Kelly WK, Ammons V, Picus J, Walling R, **Hashemi-Sadraei N**, Fu P, Margevicius SP, Adra N, Garcia JA, McKay RR, Hoimes CJ. HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer. Rapid Abstract Session at the American Society of Clinical Oncology (ASCO)-Genitourinary Cancers Symposium (GU-ASCO), San Francisco, CA, February 16-18, 2023. *J Clin Oncol* 41, 2023 (suppl 6; abstr 448)
47. Cheeti A, **Hashemi-Sadraei N**, Okino C, Cox A, Kittson R, Tawfik B, Dayao Z, Crozier N. Impact of audio-visual tool on patient comfort level at a comprehensive cancer center infusion suite: Preliminary results. Poster presented at the American Society of Clinical Oncology (ASCO) Quality Care Symposium, Boston, MA, October 27-28, 2023. *JCO Oncol Pract* 19, 2023 (suppl 11; abstr 348).
48. Barqawi YK, Borrego ME, Roberts MH, Thompson T, **Hashemi-Sadraei N**. Racial and ethnic differences in the receipt of metabolic syndrome risk factor screening and treatment among individuals with prostate cancer treated with androgen deprivation therapy. Poster presented at the American Society of Clinical Oncology (ASCO)-Genitourinary Cancers Symposium (GU-ASCO), San Francisco, CA, January 25-27, 2024. *J Clin Oncol* 42, 2024 (suppl 4; abstr 29)
49. Shilling MW, **Hashemi-Sadraei N**, Shah SK. Geographic variations in corporate sponsorship for cancer center charity events. American Society of Clinical Oncology (ASCO) Annual Meeting, May 30-June 3, 2024. *J Clin Oncol* 42, 2024 (suppl 16; abstr e23116)
50. Borrego M, Barqawi Y, Roberts M, Thompson T, **Hashemi-Sadraei N**. Longitudinal Changes in Metabolic Syndrome Risk Factors (MSRF) Screening and Treatment Rates Between 2010 and 2021 Among Patients With Prostate Cancer (PCa) Treated With Androgen Deprivation Therapy (ADT). Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Barcelona, Spain, November 17-20, 2024. (abstr 143860)
51. Abdelsamia M, Chavarin DJ, Coy J, Pankratz VS, Bernard Tawfik B, **Hashemi-Sadraei N**, Khatib J. Somatic genomic landscape of prostate adenocarcinoma at a comprehensive cancer center in New Mexico: A retrospective study (2015-2022). Accepted for poster presentation at American Society of Clinical Oncology (ASCO)-Genitourinary Cancers Symposium (GU-ASCO) 2025

Ongoing Research Support

P30 Administrative Supplement Hashemi (PI) 9/2024 – 9/2026
National Cancer Institute (NCI) Early Career Cancer Clinical Investigator Award (ECIA)
\$120,000

Role: Principal Investigator, FTE 0.4

U2C CA 252973 Hashemi (Sub-I) 9/2/2020 – Present
Participant Engagement in Cancer Genome Sequencing (PE-CGS) Research Center. Engagement of American
Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
\$18,378,678

Role: Sub-Investigator, GU disease group champion, FTE 0.05

UG1 CA 189856 Hashemi (Sub-I) 8/1/2020 – 7/31/2025
New Mexico Minority-Underserved NCORP
\$10,030,084

Role: Sub-Investigator, FTE 0.05

Mentorship, Faculty

Junior Faculty

Oct 2022 – Present Jude Khatib, MD

Division of Hematology/Oncology, Department of Internal Medicine

- Mentoring in clinic, research, and career - Weekly meetings to discuss management of her patients, review of GU oncology clinical trials portfolio, and discuss research project development. Educating her on how to critically review and evaluate protocols as well as implement protocols. Mentoring her to become an independent site principal investigator. Dr. Khatib is currently the site principal investigator for one trial, EA8192

Oct 2021 – Present Martha Mapalo, MD

Division of Hematology/Oncology, Department of Internal Medicine

- Mentoring in clinic, research, and career. Regularly discuss management of her patients with prostate cancer and review our prostate cancer trial portfolio. Weekly meetings on mentoring her as the co-chair of the Protocol Review and Monitoring Committee (PRMC) on how to critically review protocols. Regular discussions on career development.

Senior Faculty

2020 – Present Frances Alba, MD

Division of Urology, Department of Surgery

Mentoring in research. Involved Dr. Alba in the monthly Genitourinary Clinical Working Group (GU-CWG) meetings and review of GU oncology clinical trials portfolio. Mentored her on critical review of protocols as well as implementation of protocols. Assisted her in becoming the “Urology Champion” in the GU-CWG. Mentored her to become an independent site principal investigator.

Dr. Alba is currently the site principal investigator for 2 trials, EA8134 and EA8212.

Teaching/Education

Mentorship

Mentees - Fellows/Residents

- 2023 – Present Apoorva Cheeti, Hematology-Oncology Fellow, UNM
Cheeti A, **Hashemi-Sadraei N**, Okino C, Cox A, Kittson R, Tawfik B, Dayao Z, Crozier N. Impact of audio-visual tool on patient comfort level at a comprehensive cancer center infusion suite: Preliminary results. Poster presented at the American Society of Clinical Oncology (ASCO) Quality Care Symposium, Boston, MA, October 27-28, 2023. *JCO Oncol Pract* 19, 2023 (suppl 11; abstr 348).
- 2022 – Present Amir Ahmadzadeh, Internal Medicine Resident, UNM
Diagnosis of chronic kidney disease etiology through workup of Immune checkpoint inhibitor-induced renal toxicity: a case report and review of the mechanisms of renal injury –manuscript in progress
- 2021 – Present Krishna Moturi, Hematology-Oncology Fellow, UNM
Moturi K, Sharma H, **Hashemi-Sadraei N**. Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management. *Int J Mol Sci*, 2023 Dec 28;25(1):414.
Sharma, H; Moturi, RK; Pankratz, V.S.; Yilmaz, E; Gbolahan, O; Kumar, A; **Hashemi-Sadraei, N**. Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after a minimum of twelve months. *J Cancer Res Clin Onco*, 2023 Apr 28;1-8.
- 2020 – Present Harsh Sharma, Internal Medicine Resident, UNM
Moturi K, Sharma H, **Hashemi-Sadraei N**. Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management. *Int J Mol Sci*, 2023 Dec 28;25(1):414.
Sharma, H; Moturi, RK; Pankratz, V.S.; Yilmaz, E; Gbolahan, O; Kumar, A; **Hashemi-Sadraei, N**. Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after a minimum of twelve months. *J Cancer Res Clin Onco*, 2023 Apr 28;1-8.
Sharma H, Franklin M, Braunberger R, **Hashemi-Sadraei N**. Cutaneous Metastasis from Prostate Cancer: A Case Report with Literature Review. *Current Problems in Cancer: Case Reports*. 7(2022)100175
- 2019 – 2021 Shenthol Sasankan, Hematology-Oncology Fellow, UNM
Hashemi-Sadraei N, Sasankan S, Crozier N, Tawfik B, Kittson R, Abernathy J, Lauer R, Dayao Z. Improving Outpatient Infusion Clinic Wait Times at a Comprehensive Cancer Center. *JCO Oncol Pract*. 2021;17(12):e1935-e1942

Mentees – PhD student

- 2021 – Present Yazan Barqawi, PhD Candidate in Pharmaceutical Sciences, UNM
Mentored student as member of Dissertation Committee
Dissertation: Racial & Ethnic Differences in the Receipt of Metabolic Syndrome Risk Factor Screening and Treatment Among Prostate Cancer Patients Treated with Androgen Deprivation Therapy.
Bargawi YK, Borrego ME, Roberts MH, Thompson T, **Hashemi-Sadraei N**. Racial and ethnic differences in the receipt of metabolic syndrome risk factor screening and treatment among individuals with prostate cancer treated with androgen deprivation therapy. Poster presented at the American Society

of Clinical Oncology (ASCO)-Genitourinary Cancers Symposium (GU-ASCO), San Francisco, CA, January 25-27, 2024. *J Clin Oncol* 42, 2024 (suppl 4; abstr 29)

Mentee Awards

- 2022 Yazan Barqawi. Awarded pass with distinction for dissertation, Department of Pharmacy Practices and Administrative Sciences, University of New Mexico
- 2020 Shenthol Sasankan. Award for Best Presentation by Trainee, University of New Mexico Department of Internal Medicine Research Day 2020

Clinical Mentorship of Others

Although not faculty members at UNM, pod nurses, nurse navigators, advanced practice providers, research coordinators/nurses play a crucial role in medical oncology. I have been effective in the recruitment and mentorship of those joining the genitourinary team.

Mentorship Awards

- 2024 Research Mentorship Excellence Award 2023-2024, for the support of the Hematology and Oncology ACGME fellowship for University of New Mexico Comprehensive Cancer Center, Albuquerque, NM

Teaching

Fellow and Resident Teaching

- 2018 – present Repeat Lecturer and Block Leader for GU Oncology, University of New Mexico Hematology and Oncology Core Curriculum Conference for fellows - Leading GU oncology block lectures coordinating with hematology/oncology, radiation oncology, urology, and radiology; multiple subjects, 10+ sessions since July, 2018; ongoing
- 2019
- Prostate cancer-1, Localized prostate cancer, Apr 10, 2019
 - Prostate cancer-2, From castration-naïve to castration-resistant prostate cancer, Apr 17, 2019
 - Bladder cancer, Jul 31, 2019
- 2020
- Prostate cancer-1, Localized and hormone-sensitive prostate cancer, May 13, 2020
 - Prostate cancer-2, From hormone-sensitive to castration-resistant prostate cancer, May 20, 2020
 - ASCO 2020 Review of GU oncology, Sep 16, 2020
 - Bladder cancer, Oct 14, 2020
 - Renal cell carcinoma, Dec 16, 2020
- 2021
- ASCO 2021 Review of GU oncology, prostate and bladder cancer, Sep 8, 2021
 - ASCO 2021 Review of GU Oncology, renal and testicular cancer, Oct 13, 2021
 - ASCO 2021 Review of Quality of Care, Oct 13, 2021
- 2022
- Prostate cancer, from hormone-sensitive to castration-resistant prostate cancer, Mar 16, 2022

- ASCO 2022 Review of GU oncology, Aug 24, 2022
- 2023
- ASCO GU 2023 Review of GU Oncology – Kidney and Testis cancers, April 26, 2023
- 2024
- ASCO GU 2024 Review of GU Oncology

2019 Lecture, University of New Mexico Internal Medicine Residents, Prostate Cancer, Feb 28, 2019

Graduate Student Teaching

2022 – Present	Repeat Invited Lecturer, University of New Mexico, Cancer Biology Course (Bio515), (Primary Instructor: Dr. Eric Bartee) Apr 21, 2022 - Cancer Biology - the Clinical Perspective Apr 20, 2023 - Cancer Biology - the Clinical Perspective April 11, 2024 - Cancer Biology - the Clinical Perspective
----------------	---

Teaching Awards

2021	Ian Rabinowitz Award for Teaching Excellence 2020-2021, for the support of the Hematology and Oncology ACGME fellowship for University of New Mexico Comprehensive Cancer Center, Albuquerque, NM
------	---

Service

Patient Care

2018 – Present	Medical Oncologist, Genitourinary Oncology, UNM Comprehensive Cancer Center Leading GU Oncology clinic and assuring excellent patient care. This includes weekly new patient disease management meetings, biweekly genitourinary tumor boards, opening clinical trials based on the UNM CCC patient population needs, assuring compliance with ASCO and NCCN guidelines.
2023 – Present	Genitourinary Oncology Tumor Board, once every two weeks
2020 – Present	Genitourinary Oncology New Patient Triage Meeting, weekly

University, School of Medicine, Health Science Center Administrative Roles

2021 – Present	Protocol Review and Monitoring Committee (PRMC), UNM Comprehensive Cancer Center Chair, Apr 2023 – Present Co-Chair, May 2022 – Mar 2023 Voting Member, Nov 2021 – Apr 2022
2018 – Present	Genitourinary Clinical Working Group (GU-CWG), UNM Comprehensive Cancer Center <ul style="list-style-type: none"> ○ Lead, 2020 – Present ○ Committee Member, 2018 – Present
2020 – Present	Oncology Medication Subcommittee, UNM Comprehensive Cancer Center, Committee member
2020 – Present	Member, Community Oncology Clinical Working group, UNM Comprehensive Cancer Center
2019 – Present	HSC Cancer Committee, UNM Comprehensive Cancer Center, COC Cancer Liaison Physician Alternate
2019 – Present	UNM Division of Hematology / Oncology medical oncology faculty search committees, Committee member - reviewing application packets, participating in group meetings, and interviewing applicants <ul style="list-style-type: none"> ○ Radiation Oncology faculty search committee ○ GU Medical Oncology faculty search committee ○ Phase 1 faculty search committee

Local, state, regional, national committees

Oct 2022 - Present	National Cancer Institute Community Oncology Research Program (NCORP) Representative, Prostate Cancer Task Force, National Cancer Institute (NCI) Genitourinary Cancers Steering Committee (GUSC)
Nov 2018 – Present	New Mexico Cancer Research Alliance (NMCRA) <ul style="list-style-type: none"> ○ Medical Director, Aug 2024 - Present ○ Board of Directors, 2021 – Present ○ Committee member 2018 - Present
Jul 2019 - Present	Immuno-Oncology Working Group, Alliance for Clinical Trials in Oncology, Committee member
Jul 2018 - Present	Genitourinary Oncology Working Group, Hoosier Cancer Research Network (HCRN), Committee member

Clinical Trials

Active Clinical Trials

Active Clinical Trials as Site Principal Investigator

- **Alliance A031704:** PD-inhibitor (nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab: a phase III trial in metastatic untreated RENal cell cancer (PDIGREE)
- **S1823:** A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
- **S1931:** Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE)
- **NRG-GU009:** Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
- **NRG-GU010:** Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
- **NRG-GU011:** A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotheraPy with or Without ANDrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
- **HRCN GU20-444:** Neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer with selective bladder sparing
- **NRG-GU012:** Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
- **A032103:** An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThEraPy in URothelial CaNcer (MODERN)

Active Clinical Trials as Site Sub-Investigator

- **EA 8192:** A Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy (PI: Jude Khatib, MD)
- **EA 8212:** A Randomized Phase III Trial of Intravesical BCG versus Intravesical Docetaxel and Gemcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) (PI: Frances Alba, MD)
- **EA8184:** A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers (PI: Thomas Schroeder)
- **NRG-GU013:** The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer (PI: Thomas Schroeder)
- **SWOG S1912CD:** A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT) (PI: Bernard Tawfik)
- **DCP-001:** Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCORP (PI: Carolyn Muller)
- **ALLIANCE A211901:** Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
- **ASCO TAPUR:** Targeted Agent and Profiling Utilization Registry
- **NCI DCP-002:** Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations

- **SWOG S2205:** ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Included Peripheral Neuropathy
- **INST UNM 1521:** Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
- **EA 8134:** International Penile Advanced Cancer Trial (PI: Frances Alba, MD)
- **S1937:** a phase III randomized trial of eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy (PI: Jude Khatib, MD)
- **A222004:** A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

Active Investigator Initiated Retrospective Studies as Principal Investigator

- **INST CR1702:** Analysis of Single-Institution Large Experience with inhibitors of cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1)– Predictive Clinical Factors for Continued Benefit after an Immune-Related Adverse Event.
- **INST CR2103:** Prognostic Factors in Prostate Cancer Patients of New Mexico

Clinical Trials, in Regulatory to Open

Clinical Trials in Regulatory Startup as Site Principal Investigator

- **EA8211:** Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal (SOAR)
- **MK2400-001:** A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDEate-Prostate01)

Clinical Trials in Regulatory Startup as Site Sub-Investigator

- **BMS CA0711000:** A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge

Closed Clinical Trials

Closed Clinical Trials as Site Principal Investigator

- **Alliance A151804:** Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
- **Pro- STAR 1205-201:** A phase 2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/ Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
- **HCRN GU14- 188:** A Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects with T2-4aNOM0 Urothelial Cancer
- **KEYNOTE-564:** A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK- 3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy
- **KEYNOTE-866:** A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer

- **KEYNOTE-905:** A Phase 3 Randomized Study of Cystectomy plus Peri-operative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Patients with Muscle-invasive Bladder Cancer
- **KEYLYNK-010:** A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy
- **PCYC-1128-CA:** A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
- **HCRN GU17-295:** A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
- **CA209901:** A Phase 3 study of nivolumab combined with ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
- **NRG-GU006:** A Phase II, Double-blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-androgen Therapy with Apalutamide in Recurrent Prostate Cancer
- **SWOG S1216:** A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Sensitive Prostate Cancer
- **CALGB 90203:** A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
- **Alliance A031201:** Phase III Trial of Enzalutamide (NSC # 766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
- **SWOG S0931:** Everolimus for Renal Cancer Ensuing Surgical Therapy (EVEREST), A Phase III Study
- **Alliance A031203:** Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercially Supplied Sunitinib in Patients with Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
- **E2805:** Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma (ASSURE)
- **Alliance AFT-19:** A multi-center Phase 3 Study of Androgen Annihilation in High Risk Biochemically Relapsed Prostate Cancer
- **SGN22E-002:** A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
- **Alliance A031901:** Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
- **NRG-CC007CD:** Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy
- **Alliance A031902:** A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR)
- **AV-951-20-304:** Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor (TiNivo-2)
- **ECOG EA8185:** Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in clinical Stage III, Node Positive bladder cancer (INSPIRE)
- **MVT-601-056:** Relugolix Versus Leuprolide in Patients with Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)


- **A032001:** Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer (MAIN-CAV)
- **CAAA617C12301:** A phase 3 trial to compare treatment with ¹⁷⁷Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer (PSMAddition)



KUNM Radio Board Annual Report

FY: July 2023 – June 2024

KUNM listening area



Listeners per Week

The Radio Board reviews publicly available data from Nielsen Audio, Inc and CPB (Corporation for Public Broadcasting) to examine trends in listenership and voluntary listener contributions to KUNM. This is important because KUNM's contributing listeners and local program sponsors provide about **\$1.8** million of the station's annual cash budget of about **\$2.3** million.

2020 - 89,800 listeners

2021 - 89,100 listeners

2022 - 91,750 listeners

2023 - 89,400 listeners

Spring 2024 - 94,100 listeners

*On average, listeners spend 6 hours per week with KUNM. In FY 2024, people spent **25,500,000 hours listening to KUNM**. KUNM's signal reaches 1,115,000 New Mexicans. Currently, we reach just over 8 % of our potential audience. (Source: Nielsen age 12+, full week cumulative audience in total service area).*

KUNM would not be possible without the sustained support of our volunteers



- 100 student and community volunteers worked to create local content during FY2024. Many volunteers began as students and some have continued for more than 40 years.
- Collaboratives Raices and Singing Wire produce much of our local, mission driven content.
- Volunteers contribute large amounts of time to support KUNM
 - 320 hours per week (four hours of work generally are required to create 1 hour of programming)
 - Over 16,000 hours per year

KUNM would not be possible without the support of our listeners

KUNM tracks the number of individual donors contributing to the radio station each fiscal year for reporting to CPB. This information was reviewed by the Radio Board for this report.

	Donors	Total	Average Gift
FY20	7,903	\$ 1,302,200	\$ 165
FY21	8,110	\$ 1,475,200	\$ 179
FY22	8,100	\$ 1,401,800	\$ 174
FY23	6,920	\$ 1,430,880	\$ 207
FY24	7,210	\$ 1,392,747	\$ 193

Radio Board Updates



- The board approved 2 programming changes
 - Studio 505 – Replaced Home of Happy Feet (due to retirement of the show)
 - Soulful Hour – A locally produced show replaced a syndicated Art of the Song in May 2024



- The programming committee has completed the preliminary work, with the help UNM's institute for Social Research, to develop a methodology for evaluating programming as required by the bylaws. The pilot evaluation is in process
- Worked on amending the bylaws to allow a third 2-year term for all board positions
- Worked on updating the grievance procedure to align with UNM policies
- The board actively supported fundraising during the fall 2023 and spring 2024 pledge drives by providing \$1,000 challenge grants.

Radio Board Updates



- The board is working with station management and volunteers to develop a modernized draft mission statement which will align with UNM 2040
 - The Regents policy was written in 1988 and has never been updated. It does not include a mission statement, but rather a set of goals
 - KUNM seeks to align with UNM 2040, which provides a comprehensive set of goals for the university and community
 - UNM Regents would need to approve any updates to the Regents policy



KUNM Station Updates



- KUNM added new content with locally produced programming (including in-studio performances)
- KUNM continues to see success as a self-supporting department at UNM. Revenues have exceeded expenses for the past 30 years. On June 30, 2024, KUNM had a cash reserve of \$474,000 along with anticipated planned gifts totaling just over \$2,300,000.

In Memory


Claude Stephenson, longtime KUNM volunteer since 1979 who produced Folk Routes for 40 years, passed away in August of 2023

Claude was one of a kind. When he was a teenager, he left New Mexico for an extended trip back East and immersed himself in bluegrass music, which of course became a lifelong passion. He played mandolin with the Big River Boys for many years and later with Elliott's Ramblers, and many other aggregations.



His Ph.D. work focused on Matachines dances in New Mexico, and he served for a number of years as NM State Folklorist, where, among other things, he managed folklife grants, including those that for many years supported the Santa Fe Banjo & Fiddle Contest, later the Santa Fe Bluegrass & Old-Time Music Festival. He played a central role as a key advisor in establishing the Santa Fe TradFest in 2017. Claude was a long-time producer/DJ on KUNM in Albuquerque

Remembrance from Ron Hale



In Memory

Alan "Ali" Liddel passed away in 2024

First gracing the studios of KUNM in 1999, Ali had a deep knowledge of music, from the experimental to the esoteric. He was a longtime host of Fresh on Thursday evenings, where he was known for his Pink Floyd-infused station identification at midnight, as well as the fifth DJ on Global Music when the month had five Mondays. A sweet and kind man, Ali volunteered at KUNM until the end of his life. He was a super-dedicated volunteer always eager to give extra help wherever it was needed, whether subbing for Coffee Express and Freeform or assisting with news and public affairs productions.



In Memory

KUNM 's music director Matthew Finch passed away in July 2024 and was remembered by KUNM staff

KUNM staff and volunteers remembered him fondly as a great teacher, an invaluable asset to the music scene, and dedicated KUNM's recent award of Top Radio Station to him.

"I just can't imagine what the music scene will look like from here on out because he held such an important role in terms of holding the big picture of the New Mexico music scene. Albuquerque on the one hand, but really New Mexico,"
Eileen O'Shaughnessy



[Matthew Finch kept his Ear to the Ground: Remembering KUNM's longtime music director](#)



KUNM Recognitions

Fiscal year 2023-2024

- The KUNM News team has once again received multiple awards from multiple organizations for our work. These contests covered stories produced in 2023.
- Alice Fordham took second place in national news coverage for her story, “Fake 'Sober Homes' Targeting Native Americans Scam Millions From Taxpayers”, which documented how people were luring Native Americans into fake residential rehabs and defrauding Medicaid.
- Nash Jones took second place in Government and Democracy Features for their story, “Youth Legislative Session Builds Civic Knowledge and Confidence of NM High Schoolers”, about a program of the National Hispanic Institute where young people took part in a mock legislative session at the Roundhouse in Santa Fe.
- Mia Casas took first place in Student Spot News for her story, “Actors' Union Takes Its Ongoing Strike to Netflix North America’s Studios in Albuquerque”, about the New Mexico SAG-AFTRA chapter joining the national protest last summer. Mia was also recognized by the Public Media Journalists Association (PMJA) during its annual conference at NPR headquarters in Washington, D.C.
- Jeanette DeDios, who came to us through the New Mexico Local News Fund Fellows program and is now a graduate student and a full-time employee with KUNM, received eight awards from the Indigenous Journalists Association

Station Awards

KUNM won the Top Radio Station
Award at the 2024 2nd Annual New Mexico
Entertainment Awards



Looking to the future



- Richard Towne announced that he will be retiring in 2025
- The provost engaged Livingston Associates to conduct the national search for a new General Manager ([Job Posting Announcement](#))
- Livingston Associates conducted multiple listening sessions with KUNM stakeholders to understand the needs of the station
- A search committee, which includes several members of the board, was formed in late 2024 to provide input for the provost
- Candidates will be interviewed in Spring 2025



Recommendations

- ❑ KUNM continue expanding its streaming and digital content, including increasing digital availability of all programming, podcasting many locally-produced programs and promoting its internet services. Evolution of alternative formats, including streaming
- ❑ Review the KUNM Website and create a plan to update the website. In addition, review social media footprint and identify any underutilized or outdated platforms that can be implemented with a low-tech debt commitment.
- ❑ Aging and outdated facilities at KUNM are long overdue for improvement. The Board recommends that KUNM facilities be considered in the allocation of capital improvements in the 2040 UNM vision. The board also recommends proximity to the university be considered to raise awareness and engagements with UNM students, faculty, staff, and the community.
- ❑ Continue to foster recruitment for volunteers and foster creativity in programming
- ❑ Continue outreach efforts to UNM students, faculty, staff, and the community to increase awareness in KUNM. As part of outreach to students, update and align with the 2040 mission and goals, engaging more fully with students, staff and other UNM departments

KUNM remains a vital part of the University of New Mexico and the New Mexico media landscape with an active and loyal volunteer base that actively contributes to the station's success. The Radio Board remains committed to its role as an advisor to the station.

We thank the Regents, the Office of the Provost, along with UNM leadership and staff and UNM students for their on-going support for KUNM's services to the community.

This report was prepared and reviewed by the Radio Board and approved at its meeting on . The report was presented to the Regents SSTAR Committee on .

Conclusions

A New KUNM General Manager



We are delighted that Richard Towne's leadership over 30 years at KUNM has built a gem of a radio station. That gem has enabled us to recruit Jeffrey Pope to lead us into the next 30 years of broadcasting.

On June 16, 2025, **Jeffrey Pope** will take on the role of General Manager of KUNM with a carefully planned transition from our deeply appreciated current GM Richard Towne, who will be retiring.

Pope has increased relevance and sustainability of four stations, as well as of a state-wide collaborative Rocky Mountain Community Radio (RMCR), and a national public media service organization, National Federation of Community Broadcasters (NFCB). He is a place maker who, from a young age, learned to invest time and effort to make his community stronger. His mission today is to build community through story.

At Blue Ridge Public Radio, his newsroom served the community round the clock during Hurricane Helene. At KSJD in Cortez, Colorado, his team launched a news service when the area's local papers shut down. Pope has been engaged in nonprofit governance and industry leadership, serving as President of the Board of both the National Federation of Community Broadcasters and Rocky Mountain Community Radio and on the Board of Marfa Public Radio.



Board of Regents of the University of New Mexico Security Managerial Group Resolution

Pursuant to requirements of the National Industrial Security Program (NISP), the Board of Regents adopts the following resolution:

1. Those persons occupying the following positions at the University of New Mexico (UNM) shall be known as the Managerial Group for safeguarding classified information. They shall implement the Provisions of the National Industrial Security Program Operating Manual (NISPOM).

President
Provost
Facility Security Officer

2. The members of the Managerial Group have been processed, or will be processed for a personnel clearance (PCL) for access to classified information, to the level of the Facility Clearance (FCL) granted to this Institution, as provided in the NISPOM (32 CFR Part 117). Individuals will be denied access to classified information until such time that their clearances are granted.
3. The Board of Regents hereby delegates all of the Board's duties and responsibilities pertaining to the protection of classified information under classified contracts awarded to the University of New Mexico, including its Health Sciences Center and Branch Campus locations, to the Managerial Group. In addition, the Managerial Group shall have the authority and responsibility of for the negotiation, execution, and administration of the contracts, consistent with UNM policy, state, and federal law.
4. The following named members of the Board of Regents shall not require, shall not have, and will be effectively excluded from access to all classified information disclosed to the University of New Mexico. The duties and responsibilities of the Board of Regents as a policy-making body do not require access to classified contracts awarded to the University of New Mexico, and therefore need not be processed for a personnel clearance (PCL).

Regent Paul Blanchard
Regent Jack L. Fortner
Regent Victor Reyes (Student Regent)
Regent William H. Payne
Regent Paula Tackett
Regent Christina R. Campos
Regent Patricia G. Williams

This resolution is approved by the Board of Regents of the University of New Mexico on April 3, 2025 and supersedes all previous Security Managerial Group Resolutions. A copy of this resolution will be furnished to the Defense Counterintelligence and Security Agency.

Paul Blanchard
Chair of the Board of Regents

Memorandum

Date: February 6, 2025

To: Cris Elder, Faculty Senate President
Faculty Senate Operations Committee

From: Nancy D. Middlebrook, University Secretary 

Re: Request Faculty Senate Approval of Proposed Revision to Policy C140 “Extra Compensation”

The attached proposed revision of Policy C140 “Extra Compensation” was developed by the Faculty Senate Policy Committee (FSPC). In addition to placing the policy in the new *Faculty Handbook* format, the proposed revision removes the restriction that extra compensation is available only to full time faculty. This change was requested to allow extra compensation for all faculty.

The proposed policy changes were sent to the campus for a 30-day comment period. No comments were received and the FSPC approved the attached proposed revision to go forward to the Faculty Senate for approval. The Policy Committee would be happy to have a member at the Faculty Senate meeting to answer questions or concerns. Thank you for this opportunity to work collaboratively with you on this important policy.

Enclosure:
C140 “Extra Compensation” revised date 10/3/24

cc: Eve L Espey, Chair, Faculty Senate Policy Committee
Karen Patterson, Vice Chair, Faculty Senate Policy Committee



Faculty Handbook

C140 Extra Compensation

Approved By: Faculty Senate and Board of Regents

Last Updated: **Draft 10/3/24**

Responsible Faculty Committee: Policy Committee

Office Responsible for Administration: Provost and Executive Vice President for Health Sciences

Revisions to the Applicability, Policy Rationale, and Policy Statement sections of this document must be approved by the full Faculty Senate and Board of Regents.

APPLICABILITY

All UNM academic units, including the Health Sciences Center and Branch Community Colleges.

POLICY RATIONALE

The interests of the University of New Mexico (UNM) may be well served by having UNM faculty members conduct professional activities outside of their normal departmental duties. With approvals specified in this Policy, faculty members performing such activities may receive extra compensation from UNM. Prior approval of such activities for extra compensation will be contingent on the determination by the cognizant supervisors that the activities are in the best interests of UNM and that such activities will not replace or diminish the ability of the faculty member to fulfill ~~his/her~~ **their** normal contractual responsibilities.

POLICY STATEMENT

1. ~~Full-time~~ Faculty members may receive extra compensation from UNM for additional work done in connection with UNM-related activities provided that:
 - a) The faculty member wishes to pursue the opportunity for extra compensation;
 - b) Advance approval in writing is given by the chair of the faculty member's contract department and the dean or director of the College or School that houses that department; and
 - c) The work done for extra compensation does not in the opinion of the approving authorities:
 - i) Conflict in time with regular UNM duties and assignments;
 - ii) Constitute a "conflict of interest" situation for the faculty member; or
 - iii) Come within the scope of the faculty member's regular responsibilities for which compensation is already being paid.

2. The work for extra compensation does not count against the workdays allowed for outside employment. See Policy C130 ["Outside Employment and Conflicts of Commitment."](#)
3. Extra compensation using funds from research grants or contracts must conform to research policies.
4. Extra compensation for teaching beyond the scope of the faculty member's regular teaching responsibilities shall be paid through a Special Teaching Component (STC) on the regular faculty contract. Requests for contracts that include STC's shall be made prior to engaging in the activity by way of a Contract Memorandum that has the approval of the faculty member's chair or director and dean, the administrator of the department for which the special teaching is being done, and the Senior Vice Provost for Academic Affairs or the HSC Vice President for Academic Affairs.
5. Other kinds of special assignments shall be paid on an Extra Compensation Form. The rate of extra compensation will be proposed by the head of the requesting unit and should reflect fair market value for activities associated with the assignment.

Compliance

Intentional failure to comply with the provisions of this Policy will be considered a violation of UNM policy and may lead to appropriate corrective action which can include censure, warning, disciplinary probation, or dismissal, as set forth in Policy C07 "Faculty Disciplinary Policy."

Revisions to the remaining sections of this document may be amended with the approval of the Faculty Senate Policy and Operations Committee in consultation with the responsible Faculty Senate Committee listed in Policy Heading.

PROCEDURES

In consultation with the academic units, the Offices of the Provost and the Executive Vice President for the Health Sciences Center will be responsible for developing procedures for compliance with this Policy. The procedures should include the following items but may be more stringent for effective monitoring of the policy.

- Requirements for approval by the approving authority (Advance written approval is not required for periods of activity consisting of two days or less per semester)
- Requirements for STC approvals and payments
- Faculty reporting and compliance responsibilities
- Required signatory approvals
- Deans/Directors monitoring and enforcement responsibilities

Maintenance of Records and supporting documentation

DEFINITIONS

Special Teaching Component: Extra compensation for teaching outside the faculty member's contract department(s), above and beyond the faculty member's regular teaching responsibilities. A STC may not be awarded for teaching done outside faculty member's contract department(s) that is required as part of the base contract salary, for example, teaching required by the appointment contract in interdisciplinary programs or by virtue of joint or secondary appointments.

WHO SHOULD READ THIS POLICY

- Board of Regents
- Faculty
- Academic deans and other executives, department chairs, directors, and managers
- Administrative staff responsible for academic appointments and compensation

RELATED DOCUMENTS

Faculty Handbook:

Policy C07 "Faculty Disciplinary Policy"

Policy C100 "Academic Load"

Policy C110 "Teaching Assignments"

Policy C120 "Summer Teaching"

Policy C130 "Outside Employment and Conflicts of Commitment,"

Policy C180 "Special Administrative Component"

UNM Board of Regents' Policy Manual:

Policy 5.6 "Extra Compensation Paid by the University,"

University Administrative Policies and Procedures Manual:

Policy 2615 "Non Standard Payment Processing,"

CONTACTS

Direct any questions about this Policy to the Office of the Provost or the Executive Vice President for Health Sciences.

HISTORY

Amended:

October 14, 2008 – Approved by the UNM Board of Regents

Revised by the Faculty Senate in response to a request by the UNM Board of Regents

Effective:

December, 13, 1973 – Approved by the UNM Board of Regents

DRAFT HISTORY

October 3, 2024 –revising policy to allow extra compensation for part-time faculty.



OFFICE OF
THE UNIVERSITY
SECRETARY

DATE: March 19, 2025

TO: Board of Regents Student Success, Teaching, and Research Committee

FROM: Nancy D. Middlebrook, University Secretary *Nancy D. Middlebrook*

SUBJECT: Approval of Proposed Revisions to Faculty Handbook Policy C140 "Extra Compensation"

The Faculty Senate approved proposed revisions to Faculty Handbook Policy C140 "Extra Compensation" at the February 25, 2025, meeting. In addition to the policy draft, the memo sent to the Faculty Senate explaining the proposed revisions and process is attached for reference.

I am writing to request that this item be placed on the agenda for the next Board of Regents Student Success, Teaching, and Research Committee meeting for consideration.

Attachments

C140 request for approval of proposed revisions_2-06-2025

C140 "Extra Compensation" revised date 10/3/24



University of New Mexico Board of Regents
Student Success, Teaching and Research Committee
April 3, 2025

Academic Affairs Course Fee Review

Policies

Class and curricular fees, or broadly termed “course” fees, at UNM are determined by the policies spelled out in the Regents Handbook 4.7, “Tuition and Fees,” and the University Administrative Policies and Procedures Manual 8210, “Tuition and Related Fees.” The relevant portion of the policy is included as Appendix A to this report.

Broadly speaking, “class” fees are fees tied to the specific costs of delivering certain courses with distinctive expenditures. Examples include the travel costs of a field trip, the cost of particular supplies (art or lab), or special instructional materials. Since these fees fund the costs associated with the provision of a specific class, these fees are typically expended in the semester in which the costs are incurred. “Curriculum” fees, by contrast, are used for equipment and/or staff costs related to an entire course of study. Examples include IT requirements of various colleges (e.g., the unique software requirements of Architecture and Planning or Anderson School of Management); unique equipment costs (e.g., piano studios or engineering labs), or the specific technical staff required to maintain the labs and make them accessible to students.

Per policy, the Regents set the level of all tuition rates and fees that apply to all students. Class and curricular fees that apply to a specific course of study, or assessed at the class, department, or college level, are reviewed and authorized by the Provost for Main Campus and the Chancellor for the Health Sciences Center.

Procedures

A request to implement or change a class or curricular fee usually originates in an academic department. Proposals are submitted on a required template (attached as Appendix B and C) that gives the necessary technical data, along with a projected budget and description of the fee’s intended use. These are reviewed at the school/college level and require the authorization of the dean or director before being submitted to the Office of the Provost.

The review of a class or curricular fee proposal at the Provost's level has two components:

1. A review for eligibility, per the definitions of UAP 8210. We ensure the description of the fee conforms to the uses detailed in the policy, and that the projected budget is rational and defensible.
2. A consideration of the fee's impact on students, either in terms of scope (e.g., assessing a large fee for a single course) or scale (e.g., curricular fees that would affect large numbers of students). **Fee approvals are not automatic.** In practice, most eligible class fee requests are approved; however curricular fee proposals are often amended or deferred for consideration in the larger context of tuition/fee decisions.

Review

Per policy (UAP 8210.3.2.8), each college/school are to review their course fee collections and expenditures at least every two years, in order "to ensure that expenses are allowable, allocable, reasonable, and timely." This year we reviewed fiscal years 2023 and 2024 for College of Education and Human Sciences, School of Engineering, School of Architecture and Planning, College of University Libraries and Learning Sciences, Los Alamos Branch Campus, and Valencia Branch Campus. A summary of this year's reviews is attached as Appendix D.

Transparency

Course fees are published in each semester's registration schedule online and linked to every appropriate class, so that when students enroll, they get a real-time calculation of the cost of their course of study. Students may request a specific accounting of the fees they've been charged for any course or curriculum (UAP 8210.3.2.7).

Scope

Class and curricular fees are important parts of the funding streams for most colleges and schools. UNM's main campus units collected \$4,227,481 in class and curricular fees in FY24. Proportionally, that represents 1.4% of their total Instruction and General (I&G) budget. Course fees are a relatively small portion of the average student bill. According to data from the Bursar's Office, the average class and curriculum fees paid per student this fall semester was \$106, about 2.3% of the total resident full time (15+ credit hour block) undergraduate tuition bill.

Administrative Policies and Procedures Manual - Policy 8210: Tuition and Related Fees

3.2 Course Fees

Course fees are charged at the time of registration to students enrolling in specific courses. They are not included in the “mandatory fees” portion of “tuition and fees,” which are paid by all students. Requests for course fees are made to and approved by the Provost or the Chancellor. Course fees are intended to help defray costs specifically associated with certain courses, and are not intended to replace general operating costs, which are paid from tuition. All students who pay course fees must benefit from the fees charged. Course fees are listed in the “Schedule of Classes” posted on the Registrar’s Office website. At the time of registration, a student should have full information on the amount and types of course fees that will be charged for that semester.

There are two (2) types of course fees: class fees and curricular fees.

3.2.1. Class Fees

A class fee is charged to support the instructional needs of a specific course. The fee is used to pay for required, uniquely identifiable materials or services provided to students that exceed the costs of supplies normally required. Class fees may be approved and implemented if they cover any of the following expenses:

- Cost of activities related to a course (e.g., field trip, tickets to off-campus lecture or event)
- Private instruction and models (e.g., guest speakers, models, tutors)
- An object or product of value retained by the student (e.g., artwork, safety gear)
- Class costs (e.g., specialized equipment or materials, safety protections, laboratory supplies, products)

Class fees may not be used to fund any of the following costs:

- The cost of any instructor of record or assistants
- Regular classroom materials and supplies (e.g., paper, photo copies, markers, chalk)
- Faculty and staff computers, equipment, and general non-program-specific software

3.2.2. Curricular Fees

A curricular fee is charged to support curricular needs in the department, college, or school. This fee funds short-term and long-term needs for the purpose of instructing students, including technology, broadly shared materials and equipment, and other expenses relevant to multiple courses in a program. A curricular fee can be assessed as a per-credit-hour fee or predetermined

flat fee. Curricular fees may be approved and implemented if they meet any of the following conditions:

- Expendable curricular costs (e.g., computer hardware and software, networking components, cameras, projectors and recorders, maintenance fees, sound equipment, musical instruments, laboratory equipment, gross anatomy program support)
- Personnel costs associated with curriculum support (e.g., technical staff support and training course development)
- Student progress assessments, clinical or practical skills assessments, and standardized patient costs
- Supplemental instruction programs
- Support of program research requirements and student travel to present research
- Medical education computer support including provision of tutorial and standardized patient computer interfaces (HSC only)
- Develop, install, and maintain technology capabilities in lecture halls and classrooms

Curricular fees may not be used to fund any of the following costs:

- The cost of any instructor of record or assistants
- Administrative equipment and supplies
- Faculty and staff computers, equipment, and general non-program-specific software
- Equipment not used by or accessible to students
- Facility remodeling other than for classrooms and instructional labs
- Regular classroom materials and supplies
- Scholarships (except for the Music Department)
- Travel costs for faculty and staff (except when related to program-specific field trips or HSC clinical experiences)

3.2.3. Payment of Course Fees

Approved fees are collected by the University Cashier Department. Academic departments are not authorized to collect course fees directly from students. Course fees are refunded according to Section 5 of UAP 8215 (“Bursar’s Office Operations and Services”). Departmental requests to waive all or part of a course fee must be sent to the Bursar's Office and include a detailed justification.

3.2.4. Authorization to Assess Course Fees

Assessment of course fees requires the approval of the Provost or the Chancellor. Requests for all course fees must be reviewed and approved by the appropriate dean or branch director prior to submission to the Provost or Chancellor, as applicable, for approval. Subsequent approvals are not required each semester unless a change in the fee, course title, or receiving index number occurs.

3.2.5. Publication of Course Fees

All course fees, along with a brief rationale, must be published on the Bursar's Office website.

3.2.6. Review of Course Fees

Colleges, schools, and departments must review course fees at least every two (2) years to ensure that expenses are allowable, reasonable, and timely. The Provost's Office or Chancellor will submit summary findings of these reviews annually to the Board of Regents.

3.2.7. Accountability to Students

Students may submit a written request to the department, school, or college the fee resides under requesting accountability of course fees assessed. The request should state the specific fee and, in the case of class fees, the specific course number and semester. The department, school, or college will respond to the student with the information as soon as possible, but no later than sixty (60) days after receipt of the request.

3.2.8. Responsibility and Authority

The Provost's Office or Chancellor is responsible for the following functions:

- Approving course fees
- Insuring publication of course fees on the Bursar's Office website

Reviewing course fees and reporting on course fees to the Board of Regents every two (2) years.

MEMORANDUM

TO: Associate Provost for Academic Affairs/EVP of Health Sciences Office
of the Provost and EVP for Academic Affairs/EVP for Health Sciences

DATE:

FROM: *(Enter: Dean, Executive Director)*
(Enter: School/College)

RE: **Course Fee Proposal**

Please answer the following questions and provide any additional documentation that will support this proposal.

- Is this course fee a curriculum or class fee (see policy UAP 8210)?
- Reason for the new/revised fee.
- Have you paid for the expense in the past? How?
- What impact on the students/enrollments will this new/revised fee have?
- How have you communicated the proposed fee to the students? Please explain your process and provide contact information for the college/school.

My signature below confirms that I have read UAP 8210 and understand its requirements (<http://policy.unm.edu/university-policies/8000/8210.html>) as it relates to class and curriculum fees. Course Fee Approval Form and appropriate back-up documentation are attached to this request. I also maintain that the uses of these class and curriculum fees are integral to our ability to provide a flagship-level education to our students.

Dean/Executive Director Signature

Printed Name

Title

Date

THE UNIVERSITY OF NEW MEXICO – COURSE FEE APPROVAL FORM

Appendix C

INSTRUCTIONS:

For information regarding the creation of new fees as well as changes to existing fees can found in the UNM Policy 8210 available on the UNM Policy website <http://policy.unm.edu/university-policies/8000/8210.html>.

All requests for fee increases or new fees must be fully justified financially by matching projected fee revenues to the purposes specified. Examples and blank budget forms are provided on the attached sheet. If fees will be used for repair or replacement of equipment please attach a depreciation schedule found on the Provost Office website <http://www.unm.edu/~acadaffr/budget-planning/course-fees.html>. Feel free to modify or use additional budget forms as necessary.

Deadlines for receipt of requests:

Spring	First week of September
Summer	Last week of February
Fall	Last week of February

Please identify: Class Fee or Curriculum Fee (see 8210 policy)					Dept. Contact Person:					
Department:				Mail Stop Code:		Email:				
Index Number:			Program Code:		Telephone Number:					
Subject Code & Course Number	Does fee apply to all sections?	If fee is section specific, provide section #	Course Title	Effective Term	End Term (If applicable)	If cross-listed, will equal fees be assessed for all courses in the cross-list?	Current Course Fee	New/ Revised Course Fee	Index/account code (10 digits)-	Detail Code (Bursar's use only)

REQUIRED APPROVAL SIGNATURES		
Chair _____ _/ _/ _	Dean / Director _____ _/ _/ _	Approved _____ _/ _/ _ Provost for Academic Affairs
Chair (if cross-listed) _____ _/ _/ _	Dean / Director (if cross-listed) _____ _/ _/ _	FOR BURSAR'S OFFICE ONLY Processed By _____ _/ _/ _
Chair (if cross-listed) _____ _/ _/ _	Dean / Director (if cross-listed) _____ _/ _/ _	FOR OFFICE OF THE REGISTRAR ONLY Processed By _____ _/ _/ _

Sample course fee budget per student
Art Studio 100

Proposed fee		30.00
Description	Drawing materials	
Projected expenses		
	5 pencils @ 2.00/ea	10.00
	4 drawing tablets @ 5.00/ea.	20.00
Total projected expenses per student		30.00

Sample course fee budget per section
Biology 100

Proposed fee		20.00
Description	Lab supplies and equipment	
Projected enrollment		25
Projected revenue		500.00
Projected expenses		
	500 microscope slides (10/student)	100.00
	2 microscopes (1/10 th of cost of \$1,000 @ 10 yr. replacement cycle)	200.00
	Cultures	200.00
Total projected expenses per section		500.00

Course fee budget		
Section:		
	Description	Amount
Proposed fee		
Projected enrollment		
Projected revenue		
Projected expenses		
Total projected expenses		

Course fee budget		
Section:		
	Description	Amount
Proposed fee		
Projected enrollment		
Projected revenue		
Projected expenses		
Total projected expenses		

Course fee budget		
Section:		
	Description	Amount
Proposed fee		
Projected enrollment		
Projected revenue		
Projected expenses		
Total projected expenses		

Course fee budget		
Section:		
	Description	Amount
Proposed fee		
Projected enrollment		
Projected revenue		
Projected expenses		
Total projected expenses		

Review of Course Fees
Fiscal Year 2023 and Fiscal Year 2024
Appendix D
Main Campus Schools/Colleges:

College of Education and Human Sciences

School of Engineering

School of Architecture and Planning

College of University Libraries and Learning Sciences

	FY23- Actuals	FY24 - Actuals
<u>REVENUE</u>		
OA2 - Student Fees	\$ 1,033,587	\$ 1,096,365
OA6 - Other Operating Revenue	3,111	153
OP5 - Other Non Operating Revenue	29,043	23,774
OS1 - Transfers		
11C0 - Transfer from Research Gen	12,500	12,500
11H0 - Transfer To Internal Services	(5,000)	(5,000)
1240 - Transfer To Plant Fund Minor	(139,400)	(319,804)
OV1 - Allocations	(4,087)	-
OZ1 - Reserves	833,147	858,589
TOTAL REVENUE	\$ 1,762,901	\$ 1,666,577
<u>EXPENSES</u>		
OF1 - Salaries	\$ 300,896	\$ 318,639
OG1 - Payroll Benefits	46,800	44,780
OJ1 - Supplies	267,645	391,814
OJ2 - Travel	15,031	13,235
OJ3 - Student Costs	3,876	27,091
OJ4 - Research Costs	100	-
OJ5 - Patient Care Costs	-	66
OJ6 - Communication Charges	3,879	1,213
OJ7 - Services	135,356	106,396
OJ8 - Plant Maintenance	116,990	33,063
OJA - Other Expense	12,454	11,914
OM1 - Capital Expenditures	1,285	12,632
TOTAL EXPENSE	\$ 904,312	\$ 960,844
RESERVES	\$ 858,589	\$ 705,733



Review of Course Fees
Fiscal Year 2023 and Fiscal Year 2024

School/College/Branch:		College of Education and Human Sciences	
		FY23 - Actuals	FY24 - Actuals
REVENUE			
OA2 - Student Fees	\$	335,990	\$ 335,010
OV1 - Allocations		(4,087)	-
OZ1 - Reserves		289,846	287,387
TOTAL REVENUE	\$	621,750	\$ 622,397
EXPENSES			
OF1 - Salaries	\$	96,440	\$ 98,166
OG1 - Payroll Benefits		11,011	12,463
OJ1 - Supplies		26,677	71,779
OJ3 - Student Costs		100	12,900
OJ4 - Research Costs		100	-
OJ5 - Patient Care Costs		-	66
OJ6 - Communication Charges		-	943
OJ7 - Services		122,005	70,478
OJ8 - Plant Maintenance		71,594	15,337
OJA - Other Expense		6,435	4,604
OM1 - Capital Expenditures			6,714
TOTAL EXPENSE	\$	334,363	\$ 293,451
RESERVES	\$	287,387	\$ 328,946

Comments:

COEHS course fees support instructional materials, lab supplies, athletic equipment, student salaries, classroom technology, and assessment software. Remaining balances, which need to carry over across fiscal years, will be allocated for instructional needs, equipment replacement, student assessment tools, faculty support, and software licensing.



Review of Course Fees
Fiscal Year 2023 and Fiscal Year 2024

School/College/Branch:

School of Engineering

REVENUE

	FY23 - Actuals	FY24 - Actuals
OA2 - Student Fees	\$ 443,325	\$ 484,410
OA6 - Other Operating Revenue	1,189	-
OS1 - Transfers		
11C0 - Transfer from Research Gen	12,500	12,500
11E0 - Transfer to Public Service	-	-
11H0 - Transfer To Internal Services	(5,000)	(5,000)
1240 - Transfer To Plant Fund Minor	(30,150)	(252,551)
OZ1 - Reserves	308,029	456,193
TOTAL REVENUE	\$ 729,893	\$ 695,552

EXPENSES

OF1 - Salaries	\$ 14,826	\$ 18,982
OG1 - Payroll Benefits	10,650	10,995
OJ1 - Supplies	174,854	251,988
OJ2 - Travel	15,031	13,235
OJ3 - Student Costs	3,776	14,191
OJ6 - Communication Charges	3,879	270
OJ7 - Services	13,251	34,778
OJ8 - Plant Maintenance	32,392	4,120
OJA - Other Expense	3,757	4,954
OM1 - Capital Expenditures	1,285	5,918
TOTAL EXPENSE	\$ 273,700	\$ 359,431

RESERVES	\$ 456,193	\$ 336,121
-----------------	-------------------	-------------------

Comments:

Funds support maintaining, replacing, and upgrading equipment for teaching labs and student computer pods, as well as purchasing supplies, software, and services for courses. They also cover student and seminar speaker travel. Remaining balances, which need to carry over across fiscal years, will be used to upgrade engineering lab equipment to maintain ABET accreditation and to maintain a centralized reserve for unpredictable departmental needs.



Review of Course Fees
Fiscal Year 2023 and Fiscal Year 2024

School/College/Branch:		School of Architecture and Planning	
		FY23 - Actuals	FY24 - Actuals
REVENUE			
OA2 - Student Fees	\$	254,272	\$ 276,945
OA6 - Other Operating Revenue		29,043	23,774
OS1 - Transfers			
1240 - Transfer To Plant Fund Minor		(109,250)	(67,254)
OZ1 - Reserves		235,271	115,009
TOTAL REVENUE	\$	411,258	\$ 348,628
EXPENSES			
OF1 - Salaries	\$	189,630	\$ 201,491
OG1 - Payroll Benefits		25,138	21,321
OJ1 - Supplies		66,115	68,047
OJ7 - Services		100	1,140
OJ8 - Plant Maintenance		13,004	13,606
OJA - Other Expense		2,262	2,356
TOTAL EXPENSE	\$	296,249	\$ 307,962
RESERVES	\$	115,009	\$ 40,666

Comments:

Course fees in FY23 and FY24 were spent similarly on lab staff labor costs, supplies, and services maintaining equipment. All supporting the Computer and Fabrication Labs. Each year, funds are also transferred for equipment refreshes. The remaining balance at the end of FY23 was 45% of course fee revenue, reflecting a significant drawdown of prior reserves. By FY24, the balance had decreased to 15%, further reducing the large reserve from previous years. Funding needs to extend across fiscal years to support ongoing expenses and equipment updates.



Review of Course Fees
Fiscal Year 2023 and Fiscal Year 2024

School/College:	College of University Libraries and Learning Sciences	
	FY23 - Actuals	FY24 - Actuals
REVENUE		
OA2 - Student Fees	\$ -	\$ -
OA5 - Sales & Services	-	-
OA6 - Other Operating Revenue	-	-
OS1 - Transfers (please list all transfers)		
11E0 - Transfer to Public Service	-	-
11F0 - Transfer From Public Service	-	-
1240 - Transfer To Plant Fund Minor	-	-
1280 - Transfer to Plant Fund Major	-	-
OV1 - Allocations	-	-
OZ1 - Reserves	-	-
TOTAL REVENUE	\$ -	\$ -
EXPENSES		
OF1 - Salaries	\$ -	\$ -
OG1 - Payroll Benefits	-	-
OJ1 - Supplies	-	-
OJ2 - Travel	-	-
OJ3 - Student Costs	-	-
OJ4 - Research Costs	-	-
OJ6 - Communication Charges	-	-
OJ7 - Services	-	-
OJ8 - Plant Maintenance	-	-
OJ9 - Utilities	-	-
OJA - Other Expense	-	-
OM1 - Capital Expenditures	-	-
TOTAL EXPENSE	\$ -	\$ -
RESERVES	\$ -	\$ -

Comments:

College of University Libraries and Learning Sciences does not collect course fees.



Review of Course Fees
Fiscal Year 2023 and Fiscal Year 2024

School/College/Branch:

Los Alamos Branch Campus

	FY23 - Actuals	FY24 - Actuals
<u>REVENUE</u>		
OA2 - Student Fees	\$ 115,987	\$ 116,780
OZ1 - Reserves	159,763	177,344
TOTAL REVENUE	\$ 275,750	\$ 294,124
<u>EXPENSES</u>		
OF1 - Salaries	\$ 17,593	\$ 28,042
OG1 - Payroll Benefits	11,090	14,950
OJ1 - Supplies	65,991	135,119
OJ7 - Services	3,042	-
OJA - Other Expense	690	1,351
TOTAL EXPENSE	\$ 98,406	\$ 179,462
RESERVES	\$ 177,344	\$ 114,662

Comments:

Course fees support chemical supplies for wet labs, vocational training materials, art supplies, hazardous waste removal, computer hardware, and salaries for online learning and instructional technology support.

At UNM-Los Alamos, remaining balances exceeding 10% of annual course fee revenue are rolled forward as reserves for use in the next fiscal year. Significant reserves in the online curricular fee indices fund the replacement of student-facing computers and accessories on a five-to-seven-year cycle. Funding must extend across fiscal years to maintain these resources.



Review of Course Fees
Fiscal Year 2023 and Fiscal Year 2024

School/College/Branch:	Valencia Branch Campus	
	FY23 - Actuals	FY24 - Actuals
REVENUE		
OA2 - Student Fees	\$ 32,935	\$ 35,710
OZ1 - Reserves	4,663	669
TOTAL REVENUE	\$ 37,598	\$ 36,379
EXPENSES		
OJ1 - Supplies	35,567	27,947
OJ3 - Student Costs	657	774
OJ7 - Services	340	165
OJA - Other Expense	366	592
TOTAL EXPENSE	\$ 36,929	\$ 29,478
RESERVES	\$ 669	\$ 6,901

Comments:
 Course fees at UNM-Valencia are used solely for materials utilized by students in the courses. Some uses for fees include science lab materials and equipment, art supplies (easels, paints, brushes, etc.), computer hardware supplies for use in hardware installation class, etc. Remaining balances, which were minimal for FY23 and FY24 will be allocated for lab materials, equipment, and supplies that cross fiscal years.



RESEARCH

EXECUTIVE
CABINET
3.31.2025

Ellen R. Fisher, Ph.D.
erfisher21@unm.edu





Federal Research Funding Impact Report

- The Numbers
- Rapid Research Response Team
- UNM Current Research Landscape
- UNM Faculty & Staff
- UNM Students and Programs



RESEARCH

research.unm.edu/federalfunding

EXECUTIVE ORDERS

- As of March 30 | 103 Executive Orders
- At least 35 directly impact federally funded R&D

LEGAL RESPONSES


- As of March 30 | 152 legal challenges
- Responses include:
 - Temporary restraining orders
 - Preliminary injunctions
 - Many currently in appeal process



UNM RESEARCH RAPID RESPONSE TEAM


- Regular communication with campus
 - Weekly VPR Joint Communications
- Ongoing communication with congressional delegation, as well as local and state leaders
- Short term bridge funding for our most vulnerable researchers
- Responding to individual researchers' concerns
- Reviewing existing grant portfolio for “at risk” awards
- Assessing potential for “pivoting” to new lines of inquiry and/or new funders
- Monitoring funding agencies:
 - Reimbursements
 - Review panel schedules
 - Reposting of RFAs/RFPs
 - NOAs, etc.
- Close relationships with Gov Rel Team & OUC

TOTAL RESEARCH EXPENDITURES AT UNM: TRENDS



Source: National Center for Science and Engineering Statistics, Higher Education Research and Development (HERD) survey; FY24 data submitted 1/31/2025.

UNM Research: By the Numbers



FY23 data*:
average all universities ~55%; UNM was ~65%

Financial Impact of IDC rate of 15%

Estimated loss of annual F&A recovery w/ a change in IDC rate to 15% (based on FY24 amounts)


	FY24 Totals			Estimates	
	Total Federal Expenditures (1)	Modified Total Direct Costs (2)	Actual F&A Expenditures	Est. F&A Cost Recovery @ 15% or lower (3)	Est. Annual Loss in F&A Cost Recovery
Federal Direct	246,183,443.98	104,118,435.66	43,702,687.54	15,537,958.89	28,164,728.65
Federal Flow-Through:					
Foreign	119,615.87	85,126.31	32,688.54	12,768.95	19,919.59
Higher Education	19,790,016.90	12,326,759.17	6,071,077.05	1,849,013.88	4,222,063.17
Local Government	1,619,048.90	1,322,736.07	286,374.32	182,215.95	104,158.37
Non-Profit	9,613,478.44	6,098,362.62	1,608,968.25	745,338.84	863,629.41
Other Funds	40,616.83	28,033.24	12,583.59	4,204.99	8,378.60
Private - Industry/Corp	18,812,983.06	12,894,415.70	5,072,531.54	1,934,162.36	3,138,369.19
State Award	86,968,528.62	38,261,748.88	3,207,246.84	3,207,246.84	-
	383,147,732.60	175,135,617.65	59,994,157.67	23,472,910.68	36,521,246.99

- Total Federal Expenditures based on FY24 actuals for HSC, Main Campus, and Branch Campus restricted funds. Includes all federal funds, including direct and flow-through funds.
- Excludes all subaward expenses in MTDC totals in the above table. See below for definition of MTDC from Uniform Guidance 2 CFR 200.1 “Modified Total Direct Cost (MTDC)”
- Some agencies cap F&A at rates lower than 15% already. Most state awards and non-profit flow through awards cap F&A at rates significantly less than our current federally negotiated IDC rate of 52.5%, and many under 15%.


*Modified Total Direct Cost (MTDC) means all direct salaries and wages, applicable fringe benefits, materials and supplies, services, travel, and up to the first \$50,000 of each subaward (regardless of period of performance of the subawards under the award). MTDC excludes equipment, capital expenditures, charges for patient care, rental costs, tuition remission, scholarships and fellowships, participant support costs, and the portion of each subaward in excess of \$50,000.

UNM Research: By the Numbers

Personnel Supported on F&A



Archived Opportunities January 20 – March 20



155 Total Archived Opportunities


- 62.6% IDEA
- 43.9% Trainee
- 9.7% International
- 9.0% Climate/Ecological

UNM IMPACT AS OF 3.29.2025



- Stop Work Orders (SWOs) & Terminations
 - 29 SWOs (1 with 6 sub awards);
 - 11 HSC
 - 17 MC
 - 10 rescissions (all MC)
 - 8 terminations
- Financial Impact
 - \$15,808,492 for all 29 SWOs/terminations
 - \$2,552,789 on rescinded SWOs
 - \$1,362,898 posted in Banner
- More likely to come in next few weeks
 - 36 contracts from SAMHSA/CDC*: ~\$10M


Proposal Submissions January-March



Proposal Submissions

- Number down ~26% since beginning of 2025
- Represents ~40% decrease in requested funding over same period
- Impacts FY26-30

- ~\$15M to increase diversity of faculty w/biomedical research focus
 - Additional \$2M from NM Technology Enhancement Fund (TEF)
 - Support for research startup costs & building cohort
- Cohort of 9 new faculty across 5 departments (past 2 years)
 - Psychology
 - Biology
 - Chemistry
 - Speech & Hearing Sciences
 - Math/Statistics
- >\$5.2-\$8.1M at risk
 - Currently in year 3 of 5
 - Renewal Sept. 1



Dr. Anna Nelson, Mathematics & Statistics (Data Science)

*My name is Anna Nelson, and I became a mathematical biologist because I want to mentor the next generation of mathematicians. I am a firm believer in the strength of community and would not have made it to where I am without the advocacy of my personal and academic mentors who guided me during many hardships. **Through failing exams, transferring various academic programs, and family illnesses, my mentors were there to illuminate the paths before me.** Therefore, I am dedicated to paying it forward, and to show students and mentees what is possible in mathematics and biology in this increasingly computational world. I believe in the strength of community and believe that human health can be improved with mathematics and close-knit collaborations.*



Laura Ornelas, Psychology (Neuroscience)

*My name is Laura Ornelas and I was born and raised in Austin, Texas. My millennial generation has encountered many major economic, social, geopolitical, and/or health and safety challenges, all of which have occurred throughout every developmental and age period of our lives from childhood, adolescence and adulthood. The impact these stressors, traumatic events, and significant global events have had on my generation is consequential and we are seeing the lasting effects these events are having on mental health stability and increased substance use. It is well known that consumption of alcohol is used as a short-term coping mechanism to alleviate symptoms of stress, anxiety and fear. **My research is not just a profession, it is personal as I have seen the significant impact traumatic events have had on my generation specifically with substance use. Understanding the neurobiological mechanisms that underlie stress coping and maladaptive alcohol drinking may provide more effective and sex-specific clinical prevention and treatment strategies for individuals with PTSD and comorbid alcohol use.***

Dr. Anisha Shakya, Chemistry & Chemical Biology (Neuroscience)



*Born and raised in Nepal in a patriarchal society by economically struggling parents, **I thought it was a monumental achievement for me when I received a Ph.D. from a prestigious university in the United States. I was wrong. I was shattered into pieces three years ago when my perfectly healthy full-term pregnancy ended in a stillbirth, I almost losing my life. My real achievement was working through that immense grief and trauma of losing a daughter I never even got to hold, building myself back up, and keeping alive my dream of being a successful scientist while having a family.** Now I am a mother to a 1-year-old boy and an assistant professor at UNM – both roles that I am incredibly grateful to have and at which I am committed to be successful.*



Noncompeting Training Grant


Main Campus

- NIH PREP@UNM
 - Postbaccalaureate Research Education Program*
 - 17 years @UNM
 - Has supported more than 110 scholars
- Over 50 sites nationwide
 - ~80% placement in Ph.D. or MD/Ph.D. programs
 - Well above most other PREP programs
- Currently 7 trainees, program manager supported
 - Year 2 of 5-year grant (grant year 3/1-2/28)
 - No NOA to date (expected February 2025)



*NEI PREP program on list of archived opportunities

NIH REPORTER: NUMBER OF AWARDS RELEASED JAN. 21 – MARCH 21, 2024 VS 2025



EXAMPLES OF UNM HSC PENDING TRAINING GRANTS

- **T32 Initiative for Maximizing Student Development (IMSD)***
 - Supports 15 students for 3 years including years 1–3 of the Ph.D. program
 - Just ended year 3 of 5. We are waiting for the NOA for year 4 as of Feb. 1
- **T32 Training Program for Institutions that Promote Diversity (Year 4 of 5)***
 - We were planning to apply to the following RFA which expired 1/19
 - It was replaced by another RFA and the word “diversity” was removed
 - Dates to 1993 and supports 6 Ph.D. students & 2 postdoctoral scholars
- **CY 2025 UNM HSC is expecting a total of \$42,083,459 from NIH**
 - Training grants: \$10,987,602
 - At risk IDEA: \$9,673,701
 - 41 trainees

Jorge Moreno | Moreno is a third year Ph.D. student in the COP in the laboratory of UNM Assistant Professor Alicia Bolt. Moreno joined the Biomedical Sciences Graduate Program (BSGP) in 2022 after completing a bachelor's degree in Biology as a first-generation college student at the University of Texas San Antonio. He worked for four years at Hyperion Biotechnology toxicology laboratories before joining UNM. At UNM he is currently studying the effect of heavy metal exposure on the development and progression of autoimmune responses and breast cancer. He recently passed his comprehensive exam and is on track to complete his Ph.D. in 2028, but scheduled to move off the IMSD grant in July 2025.



Sydnee Yazzie | Yazzie is a third year Ph.D. student in the department of Pathology withing the SOM laboratory of UNM Assistant Professor Katherine Zychowski. Yazzie is a native of Gallup and attended Eastern New Mexico University where she earned a bachelor's degree in Biology before joining the BSGP in 2022. Yazzie's project is studying the impact of wildfire smoke and environmental uranium on cardiovascular and reproductive health. Yazzie is on track to complete her Ph.D. in 2028 or 2029, but scheduled to move off the IMSD grant in July 2025.

Xavier DeLeon | DeLeon is a second year Ph.D. student in the SOM laboratory of UNM Professor Nikki Jernigan in the Cell Biology and Physiology Department. He received a bachelor's degree in Biology from UNM and then spent more than 10 years working as an educator. He returned to UNM as a graduate student, father and is currently balancing many roles while studying a novel signaling pathway that predisposes to obesity and metabolic disease. DeLeon is scheduled to move off the grant in July 2026 but won't graduate until 2028.





UNM CASH FLOW: IMPACT ON RESEARCH

- Federal agencies must now review/approve every transaction
- Delays in payments: Increased burden on research administrators & PIs
 - DHHS expenditure reimbursement (March) totaled \$5.9 million for 185 funds.
 - NASA: March expenditure reimbursement totaled \$278K for 9 funds.
 - FEMA: Must do an amendment every month w/billing and other information before we can submit payment request
 - We have not been paid for requested Jan reimbursements (\$126K); cannot make request for Feb (\$111K) (8 active awards)
- Will not know full extent until all Federal agencies provide requirements and we can track how long it takes to receive payments.
 - National Science Foundation \$2.4M for reimbursement
 - Department of Education \$5.3M including \$3.7M for Financial Aid


TODAY & TOMORROW IMPACTS

- Impact of delays in receiving requested payments:
- Based on ~\$30M/month request for drawdown
 - 30 days: \$44,055
 - 45 days: \$66,082
 - 60 days: \$88,110
- Department of Education grants
- 36 active grants
- Total anticipated: \$52,489,893
- Total through current award year: \$29,577,874
- Remaining for FY26 & beyond: \$22,912,019




UNM Graduate Students


- Graduate ***applications***: Do not seem to be impacted:
 - Overall, grad applications are up significantly for this year versus last year
 - Most programs had application deadlines in December and January
- Grad ***enrollments***: Currently unknown.
 - In the middle of admissions season | Grad students nationwide have until Apr 15 to accept funding and admissions offers
 - Enrollment numbers come out in May




Master's
applications
are up by
5%



Master's
Admission
offers are up
by **only 2%**



Ph.D.
applications
are up by
12%



Ph.D
Admission
offers are
down by 5%

➤ **Grad Level Funding:**

- Many/most masters students are self-funded.
- At the doctoral level, students are much more likely to rely on funding packages/offers in making the decision to start a graduate program.

➤ **UNM Program Admission Decisions:**

- UNM Grad Studies: Programs should NOT systematically change approach to admissions or cut back on number of offers
- Programs asked to make sure they had an identified funding source before making funding offers.
- In the past, standard practice was to admit students without knowing definitely where future funding would come from (i.e., offering a 3-year funding package to prospective PhD student even though a faculty member's grant is for 2 years; thus, relying on expectation of future funding identified by year 3).
- Most departments at UNM did not feel this was a wise choice in the current climate. This is a likely contributor to the contraction in offers.



***“...collaborative,
it’s the co-creation
of knowledge.”***

***– UNM
Postdoctoral
Fellow Divana
Olivias***

***“...making those things we once
thought were impossible,
possible” – UNM Professor
Richard White***

RESEARCH IS...

***“...offering an unapparelled
experience for our students”
– UNM Associate Professor Yi He***

***“...not just a job...”
– Amera Abu
Kabeer, UNM
Research
Administrator***

***“... to build upon the
foundation we’ve been given
and build an even better
foundation for future
researchers” – UNM Undergrad
Jacob Dawes***



“...thinking about how you can be of service to the community” – UNM Research Assistant Megan Joe



Community Engagement Initiatives



OFFICE OF COMMUNITY ENGAGEMENT



Tim B. Castillo

**Director, Community Engagement
Initiatives**

Professor of Architecture
University of New Mexico



Alish Dogra

Media Specialist
University of New Mexico



Karol Ibarra Zetter

Program Coordinator
University of New Mexico



Refat Mishuk

Data Specialist
University of New Mexico

The Elective Classification for Community Engagement



Defining Community Engagement

Community engagement describes collaboration between institutions of higher education and their larger communities (local, regional/state, national, global) for the mutually beneficial exchange of knowledge and resources in a context of partnership and reciprocity. The purpose of community engagement is the partnership of college and university knowledge and resources with those of the public and private sectors to enrich scholarship, research, and creative activity; enhance curriculum, teaching, and learning; prepare educated, engaged citizens; strengthen democratic values and civic responsibility; address critical societal issues; and contribute to the public good.



THE UNIVERSITY OF
NEW MEXICO.

THE UNIVERSITY OF NEW MEXICO

2013-2020 COMMUNITY ENGAGEMENT INITIATIVES

December 2019

Office of Community
Engaged Learning &
Research

Monica Kowal, Ph.D.
Director, Community
Engagement Initiatives

kowal1@unm.edu
(505) 277-7186

COMMUNITY ENGAGEMENT AT UNM

Completing the University of New Mexico's application for the 2020 Elective Classification for Community Engagement from the Carnegie Foundation was a significant undertaking and culminated nearly eight years of institutional policy initiatives and growth. The Carnegie Foundation explicitly states that the application and classification are not just about campus offices or centers for this type of work. The application and classification represent engagement practices and partnerships across the university so that if a university receives the classification it truly signifies an entire campus as engaged, from policy to practice, embodying our mission as a public research university into agency and action. UNM is certainly an institution that can tell its own story of engagement. This report is a record of initiatives led by the Office of the Provost in concert with representation from faculty and administrators from across campus.


While our 2020 Carnegie application paints a picture through data and description of student and community impact, the work that is necessary to build upon this momentum is not complete. Recognition and support for faculty, evidence of an institutionalized value system, and a strong campus-wide infrastructure that demonstrates communication, accountability, data collection, and assessment are still needed. To become a truly engaged campus, UNM must integrate partners and partnerships into the life and culture of the university so that partners are not seen as separate from the educational force but a part of it.

A handwritten signature in black ink that reads 'Monica Kowal'.

Monica M. Kowal, Ph.D.
Director, Community Engagement Initiatives, 2013-2018

Elective Classification for Community Engagement 2015, 2020, and 2024

368 Currently Classified Institutions



Private Public Closed Consolidated



James Holloway

Provost & Executive Vice President
or Academic Affairs


UNM Community Engagement Advisory Board



Manuel Montoya
[College of A & S Economics]



Katie Dukes Walker
[College of Fine Arts]



Levi Romero
[College of A & S-C & C Studies]



Nina Walerstein
[College of Population Health &
Center for Participatory Research]



Rebecca Sanchez
[College of Education &
Health Sciences]



Renia Ehrenfeucht
[School of Architecture & Planning]



Troy Lovota
Honors College]





GOAL ONE

ADVANCE NEW MEXICO:

Understand the needs and unique opportunities of our distinct New Mexican cultures and peoples, economic enterprises, and communities to address critical issues and opportunities facing humanity and contribute to the quality of life, growth, prosperity, and advancement of New Mexico and of human societies across the globe.



OFFICE OF
COMMUNITY
ENGAGEMENT

Initiatives



Community Engagement

[Learn More about Engagement](#)

COMMUNITY ENGAGEMENT SYMPOSIUM 2023



Date: November 3, 2023

Time: 1:00-5:00 pm (Reception 5:30-6:30)

Location: George Pearl Hall (Architecture + Planning)

Keynote: Lt. Governor Howie Morales

Panel Speakers:

Priscilla Lucero

Director, Southwest New Mexico Council of Governments

Erin Callahan

Deputy Village Administrator, Village of Los Lunas

Patricia Trujillo

Acting Cabinet Secretary, New Mexico Higher Education Department

Celeste Nuñez

Director of International Business Resources, New Mexico Trade Alliance

Ted Jojola

Director, Indigenous Design + Planning Institute

Kiran Katira

Director, Community Engagement Center

Shannon Sanchez-Youngman

Associate Director, Center for Participatory Research

Robert G. (Rob) DelCampo

Executive Director of Corporate and Community Engagement

Keynote-Lt. Governor-Howie Morales



Community Partners



Priscilla C. Lucero
Executive Director,
SWNM Council of Governments



Patricia Trujillo
Cabinet Secretary
New Mexico
Higher Education Department




Erin Callahan
Deputy Village Administrator
Village of Los Lunas



Celeste Nuñez
Director
International Business Resources
New Mexico Trade Alliance

Community Engagement
Institutes & Centers



Ted Jojola

Director
Indigenous Design +
Planning Institute
Professor, Community
Regional Planning



Shannon Sanchez-Youngman

Associate Director
Center for Participatory Research
Assistant Professor
College of Population Health



Kiran Katira

Director
UNM
Community Engagement Center



Rob DelCampo

Executive Director
Corporate & Community Engagement
Professor
Department of Management



2024 Community Engagement Week

APRIL 1 - 5

April 1 & 2, 2024 page 2
OFFICE OF COMMUNITY ENGAGEMENT
Elevating Community
Engagement at UNM

April 3 & 4, 2024 page 3-8
CENTER FOR TEACHING & LEARNING
Spring Teaching Conference
Community-Engaged
Teaching & Learning

April 5, 2024 page 8
UNM Community
Engagement
Center Annual
Symposium



COMMUNITY ENGAGEMENT

SYMPOSIUM 2024

“BREAKING BARRIERS”



OFFICE OF
COMMUNITY
ENGAGEMENT




KEYNOTE

Cammie Jones-Friedrichs

Director, Carnegie Elective for Community Engagement

Elective Classification for Community Engagement 2015, 2020, and 2024

368 Currently Classified Institutions



● Private ● Public ● Closed ● Consolidated



OFFICE OF
COMMUNITY
ENGAGEMENT

Data Collection and Assessment

Carnegie Foundation Elective Reclassification

As part of our ongoing commitment to enhancing community engagement at the University of New Mexico, we are preparing the report for the elective reclassification of the Carnegie Foundation for Community Engagement.


This submission is due April 1st 2025, and it is crucial that we gather comprehensive data on our community engagement activities across the state of New Mexico, the region and in our local communities.

To ensure our report is accurate and comprehensive, we kindly ask for your support in providing information about your community engagement initiatives. These activities may encompass, but are not limited to:

- Outreach programs
- Service-learning projects
- Community Based Participatory Research
- Collaborative research with community partners
- Public service activities
- Any other initiatives that contribute to community well-being and development

Your input will play a pivotal role in demonstrating the breadth and depth of our community engagement efforts, thereby strengthening our case for reclassification. Please submit your data by January 31st 2025, using the corresponding survey link provided by the Office of Community Engagement.


- [Chairs survey](#)
- [Faculty survey](#)
- [Centers and Institutes](#)
- [Museums](#)





OFFICE OF
COMMUNITY
ENGAGEMENT

Community Engagement Impact Map

Welcome to the University of New Mexico's Community Engagement Impact Map. In collaboration with the Earth Data Analysis Center, the interactive data map demonstrates the extensive commitment UNM has to serving communities. The Office of Community Engagement at UNM is dedicated to telling the stories of how we are partnering with communities to develop solutions that address the challenges facing society. We invite you to engage the interactive geospatial data set.





< 1/1 >

Salt of the Earth Recovery Project

PI/Lead
Michelle Kells

Contact Info
mkells@unm.edu

Location
Grant

Year(s)



Indigenous Design + Planning Institute



Evaluation Lab



College of Population Health



Department of Africana Studies



Rural and Urban Underserved Program School of Medicine

2015/07/12



Center for Native American Health



McKINNON CENTER FOR MANAGEMENT

Innovation Academy



R.H. Mallory Center for Community Geography



Native American Studies



Project Echo



Chicana & Chicano Studies



Southwest Environmental Finance Center



Design Planning Assistance Center



OFFICE OF
COMMUNITY
ENGAGEMENT

**UNM METALS**

Director, Dr. Jose Cerrato
Professor & Regents' Lecturer
Civil, Construction and
Environmental Engineering

**Project: METALS Community Liaisons Through Non-Profit SRIC
(Southwest Research and Information Center)****Community Partner: Southwest Research and Information
Center**

The project aims to assess and mitigate the environmental and health impacts of uranium and other heavy metals in communities, which have been disproportionately affected by mining and other industrial activities.



Lorenda Belone,
PhD, MPH
Professor
College of Public Health

Project: Family Listening Program (FLP) Community-Based Participatory Research Culturally-Centered Implementation Project

Community Partner: Ramah Navajo Prevention Program

This is a research study funded by the National Institute of Health (NIH) works with partners across Jemez Pueblo, Ramah Navajo, Mescalero Apache, Nahata Dził, Torreon, and Santa Pueblo to support families with curriculum driven by community needs and perspectives.



Tiffany Lee, PhD
Professor
Native American Studies

Project: New Mexico Public Education Department Partnership for Diné Language Teachers Institute

Community Partner: Indian Education Department and Albuquerque Public Schools

The Diné Language Teacher's Institute focuses on professional development for educators teaching the Diné (Navajo) language.



OFFICE OF
COMMUNITY
ENGAGEMENT

Institutes & Centers



Indigenous Design + Planning Institute

[Home](#) [About](#) [Projects](#) [Academics](#) [Professional](#) [Tribal](#) [Happenings](#) [Donate](#)

Indigenous Design + Planning Institute



We promote self-reliance through innovative training
and assistance focused on actionable results.

[Visit our new Water, Wastewater, and Stormwater Assistance Program Webpage >](#)

Center for Native American Health



For Students ▾ For the Campus ▾ For the Community ▾ 🔍 ≡



Center for Native American Health

The UNM HSC Center for Native American Health specializes in student and workforce development, community engagement, community-based participatory research (CBPR), community health assessment capacity building, program planning, and project management.



Signature Programs

We partner with students, staff, faculty, community groups, organizations, and government agencies to develop sustainable solutions and creative pathways for improving the health and well-being of Indigenous people. CNAH approach focuses on community strengths such as local and unique knowledge, core cultural value systems, and health beliefs.

Featured Faculty



Maria Lane

Dean, Graduate Studies



Caroline Scruggs

Associate Professor, Community
and Regional Planning (CRP)



**Dr Kimberly
Gauderman**

Associate professor of Latin
American History



Levi Romero

Associate Professor, Chicana and
Chicano Studies



Tiffany Lee


Professor Native American Studies



OFFICE OF
COMMUNITY
ENGAGEMENT



2026 Carnegie Elective Classification for Community Engagement Application Timeline





Future Vision

UNM CE Academy



Nina B. Wallerstein, Dr. PH
Distinguished Professor of Public Health
Director, Center for Participatory Research



Michaelae Pride
Professor, Associate Dean & Director,
Design Planning Assistance Center
School of Architecture and Planning



UNM CE Academy




Community Engagement Work Session 2025

On January 31, 2025, we gathered for the Community Engagement Work Session 2025, where Nina Wallerstein, Michaela Pride led an insightful presentation on fostering meaningful community partnerships. This was followed by the River of Life interactive activity, where participants reflected on their personal and professional journeys in community engagement. From inspiring discussions to personal storytelling, this session brought together diverse perspectives to strengthen our collective impact.



OFFICE OF
COMMUNITY
ENGAGEMENT

External Advisory Board



OFFICE OF
COMMUNITY
ENGAGEMENT

CE Student Resources & Opportunities



OFFICE OF
COMMUNITY
ENGAGEMENT

CE Publication/Products Archive



OFFICE OF
COMMUNITY
ENGAGEMENT

CE Student Course Designation



OFFICE OF
COMMUNITY
ENGAGEMENT

Tenure & Promotion



OFFICE OF
COMMUNITY
ENGAGEMENT

**Community Engagement Office
2nd Floor (#233) George Pearl Hall**



Photograph by Kirk Gittings



**OFFICE OF
COMMUNITY
ENGAGEMENT**



OFFICE OF COMMUNITY ENGAGEMENT

Contact:

Tim Castillo

Director

timc@unm.edu

Karol Ibarra Zetter

Program Coordinator

karol@unm.edu

Website:

engagement.unm.edu